Endothelial dysfunction in congenital adrenal hyperplasia due to 21-hydroxylase deficiency: current knowledge and novel biomarkers

Abstract

Congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency (21OHD) is a complex endocrine disorder characterized by impaired cortisol synthesis and androgen excess. Beyond its hormonal and metabolic implications, CAH has been increasingly associated with an elevated risk of cardiovascular complications, including endothelial dysfunction, a critical precursor to atherosclerosis and a risk factor for cardiovascular and metabolic diseases. This review explores the current knowledge on endothelial function in patients with CAH, focusing on the interplay between chronic hormonal imbalance, prolonged glucocorticoid treatment, and associated metabolic disorders. We also discuss in vivo methods for assessing endothelial function alongside the potential utility of novel biomarkers, which may facilitate earlier identification of vascular dysfunction and stratification of cardiovascular risk. By summarizing emerging concepts in this field, we aim to highlight areas for future research and opportunities for improving long-term cardiovascular outcomes in individuals with 21OHD.

1 Introduction

Congenital adrenal hyperplasia (CAH), due to 21-hydroxylase deficiency (21-OHD), is an autosomal recessive condition that is caused by mutations in the gene CYP21A2. It is characterized by impaired cortisol secretion and androgen excess. 21-OHD is the most common cause of CAH, accounting for 95% of cases (1). Based on the residual enzyme activity, CAH shows a spectrum of phenotypes, varying from a severe classic CAH (CCAH), usually diagnosed in newborns, to a non-classic CAH (NCCAH), which is a mild variant often diagnosed late, if ever. CCAH is classified into two forms based on aldosterone deficiency: salt-wasting (SW) and simple virilizing (SV). The primary treatment for CAH, particularly CCAH, involves glucocorticoid and mineralocorticoid replacement to prevent adrenal crises and manage excess androgen production. Achieving a balance between these treatments is essential to avoid both under- and over-treatment, as both extremes can have detrimental effects on long-term metabolic and cardiovascular health. However, even in an era of continuously advancing knowledge about CAH, improved patient care, and the availability of effective treatments, such as those mimicking the circadian rhythm of cortisol, the presence of CAH remains associated with numerous metabolic complications and increased cardiovascular morbidity (2).

Mounting evidence has shown that the dysfunction of endothelial cells in the vasculature is profoundly implicated in the pathogenesis of cardiovascular and metabolic diseases (3). Furthermore, there is a bidirectional relationship between endothelial dysfunction and these disorders. Components of metabolic syndrome, such as abdominal obesity, hypertension, and impaired glycemic control, can contribute to endothelial dysfunction (4). Conversely, structural and functional changes in the endothelium promote the progression of metabolic diseases and atherosclerosis (5). Given the hormonal imbalances and systemic effects of CAH, understanding its potential impact on endothelial function is crucial, as individuals with CAH are at higher risk for these conditions (6, 7).

Despite the growing body of evidence linking CAH to endothelial dysfunction, significant research gaps persist. To date, no studies have systematically assessed the relationship between endothelial dysfunction and glucocorticoid dose, type, or treatment duration. Importantly, the differential impact of various chronic glucocorticoid replacement regimens on endothelial function has not been evaluated in controlled studies (8). Moreover, the progression of endothelial dysfunction over time in individuals with CAH remains insufficiently understood. To date, no randomized controlled trials have been conducted in this area, and no meta-analyses are available to synthesize the existing evidence.

In this review, we provide an overview of current knowledge on endothelial function in individuals with CAH, with a particular focus on the factors that contribute to endothelial damage, methods of endothelial assessment, and novel biomarkers that could help to detect patients at higher risk. We also discuss gaps in knowledge and areas for future research.

2 Endothelial dysfunction and its role in cardiovascular disease

The endothelium, a single-cell layer lining the inner surface of blood vessels, plays a vital role in maintaining vascular homeostasis. The endothelium releases various autocrine, paracrine, and endocrine substances, such as nitric oxide (NO), C-type natriuretic peptide, prostacyclin, and endothelium-derived hyperpolarizing factor (9). These factors collectively inhibit smooth muscle cell proliferation and migration, prevent platelet adhesion and aggregation, and regulate processes that influence thrombogenesis (10).

Endothelial dysfunction involves a shift in endothelial cell behavior, leading to various maladaptive changes in their functional phenotype. This results in disturbances in the regulation of hemostasis, thrombosis, vascular tone, redox balance, and inflammatory processes (11). The underlying pathophysiology is multifaceted, involving several mechanisms.

A key factor in the development of endothelial dysfunction is oxidative stress, which arises from multiple enzymatic sources such as xanthine oxidase, NADPH oxidases, uncoupled endothelial nitric oxide synthase (eNOS), and malfunctioning mitochondria. It occurs when the balance between pro-oxidants and antioxidants is disrupted (12). Elevated reactive oxygen species (ROS) levels can oxidize cellular macromolecules and reduce NO production by promoting the formation of peroxynitrite (12), a toxic compound that degrades the eNOS cofactor tetrahydrobiopterin (13), leading to the “uncoupling” of eNOS and increased oxidative stress. This oxidative imbalance also contributes to impaired endothelial vasodilation and a proinflammatory environment, as well as the upregulation of adhesion molecules such as intercellular adhesion molecule 1 (ICAM-1) and vascular cell adhesion molecule 1 (VCAM-1), along with chemotactic molecules (12) (Figure 1).

Figure 1

Inflammation plays a crucial role in the pathogenesis of cardiovascular disease (14). In response to vascular injury, endothelial cells release a variety of inflammatory molecules, including chemokines, interleukin-8, colony-stimulating factors, monocyte chemoattractant protein-1 (MCP-1), adhesion molecules such as ICAM-1 and E-selectin, and growth factors and other inflammatory mediators (15), leading to the attachment of monocytes and their migration into the vessel wall. Monocyte-derived macrophages ingest oxidized low-density lipoprotein (LDL), forming foam cells and fatty streaks, which lead to the development of plaques affecting the coronary arteries, aorta, and carotid arteries, ultimately resulting in atherosclerosis (16). This cascade promotes the adhesion and migration of leukocytes across the endothelial barrier, further activating an inflammatory state (17). In addition, proinflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) are released by endothelial cells, activating a vicious circle (18).

Endothelial dysfunction is often widespread throughout the body, as individuals with diagnosed atherosclerosis frequently exhibit endothelial dysfunction in peripheral vascular regions that may not yet show overt signs of the disease. It is also observed in those with a family history of early cardiovascular disease despite the absence of other risk factors (19); in individuals with hypertriglyceridemia (20), dyslipidemia (21), nicotine use (22), and insulin resistance (23, 24); first-degree relatives with type 2 diabetes; and elderly patients regardless of the presence of other comorbidities (25). The advancement of endothelial dysfunction is influenced by the severity and duration of established risk factors and the overall risk profile of individual patients (26).

3 The risks for endothelial dysfunction in CAH

The exact mechanisms behind the higher prevalence of cardiometabolic risk elements in patients with CAH remain unclear. Nonetheless, both disease-related and treatment-related elements are being discussed. Importantly, cardiovascular disease is the second most common cause of death in patients with CAH after adrenal crisis (27), and is closely linked to endothelial dysfunction (28).

Individuals with CAH are at an increased risk of developing metabolic syndrome, which is characterized by a cluster of metabolic abnormalities, including central obesity, insulin resistance, hypertension, and atherogenic dyslipidemia (29) (Figure 2). Obesity is the most common component of metabolic syndrome in both children and adults with CAH and acts as a major independent risk factor for cardiovascular diseases (1). In patients with CAH, the prevalence of obesity ranges from 30% to 40% (30–34). It contributes to endothelial dysfunction through associated complications such as hypertension, dyslipidemia, type 2 diabetes, and obstructive sleep apnea (35, 36). The excess fat accumulation in obesity leads to adipocyte dysfunction, triggering oxidative stress and insulin resistance, while also serving as a source of pro-inflammatory cytokines, all of which contribute to endothelial dysfunction (36, 37). Additionally, patients with CAH are more likely to develop increased visceral adipose tissue, a well-established risk factor for cardiovascular diseases (38).

Figure 2

Notably, endothelial dysfunction is a key component of metabolic syndrome, with involvement in both the initiation and propagation of this condition (39). In patients with CAH, these abnormalities arise from cortisol deficiency, excess androgen secretion, and hypercortisolism due to possible glucocorticoid overtreatment. Additionally, dysfunction of the adrenomedullary system, marked by deficient epinephrine secretion, may contribute to reduced lipolysis of triglyceride stores and disruptions in insulin and adipokine regulation (40–42).

Abnormal androgen levels in CAH should be considered among the risk factors for endothelial dysfunction (Figure 2). Both hypoandrogenism in male patients and hyperandrogenism in female patients can contribute to adverse metabolic effects, thereby increasing cardiovascular risk (43–45). Arlt et al. (31) found that the majority of patients with CAH exhibited either elevated or suppressed androgen levels, with only 36% showing normal androstenedione levels. The detrimental effects of androgen excess in CAH were further confirmed in a cohort of women with CCAH SV untreated with glucocorticoids; insulin resistance and unfavorable metabolic markers were notably increased in these patients compared to the control group, and showed a direct correlation to testosterone levels (46). Paizoni et al. (30) also supported the role of androgens in insulin resistance development in women with CCAH, especially in those with poor androgen control. Similarly, there are studies in NCCAH that emphasize the relationship of increased testosterone levels with insulin resistance (47). Moreover, studies in patients with polycystic ovary syndrome (PCOS) have shown a link between hyperandrogenism and impaired endothelial function (48, 49), suggesting that elevated androgen levels may significantly contribute to endothelial dysfunction.

Hypertension is another major risk factor for cardiovascular disease, and in CAH, an increased frequency of hypertension overall is observed across age groups, although more prevalent in children compared to adults (50, 51). Importantly, the relationship between systemic arterial hypertension and endothelial dysfunction is bidirectional, amplifying the severity of both conditions. Endothelial cells influence the development of systemic hypertension through various mediators, while systemic hypertension exacerbates endothelial dysfunction, contributing to a prothrombotic, proinflammatory, and proatherosclerotic state (52). It is well established that excess glucocorticoids can elevate arterial blood pressure mainly through mineralocorticoid mimetic effects, vascular remodeling, and impaired NO signaling (53). However, the role of mineralocorticoid treatment should also be considered; patients with CAH receiving fludrocortisone tend to experience elevated blood pressure more frequently than those who do not (54).

The majority of studies have reported elevated blood pressure values in patients with CAH (32, 55, 56). In youth with CAH, a positive correlation between body mass index (BMI) and blood pressure has been observed (57, 58), highlighting a significant association between hypertension and obesity in this population. Furthermore, even in the absence of clinically overt hypertension (47), individuals with CAH may show a reduced physiological nocturnal dip in blood pressure (30, 59, 60). Gender differences have been examined in a limited number of studies, with most finding a similar prevalence of hypertension between men and women with CAH (32, 61–63). However, two studies suggested that women with CAH may be more affected than men, likely due to excessive androgen exposure (47, 64).

The cardiometabolic status in CAH is strongly affected by the medications used in therapy, as the mainstay of CAH management involves the intake of glucocorticoids and mineralocorticoids (Figure 2). The doses should be substitutive; however, patients frequently fail to adhere to the guidelines. Excessive intake of glucocorticoids and mineralocorticoids can raise cardiovascular risk factors, while inadequate glucocorticoid therapy or poor adherence may result in androgen excess, infertility, and the formation of adrenal rest tumors (65, 66). Therefore, preventing long-term metabolic and cardiovascular complications depends on maintaining an optimal balance between overtreatment and undertreatment, however, it remains a significant challenge in both CCAH and NCCAH (67).

Chronic glucocorticoid therapy has been shown to heighten the risk of developing insulin resistance and, subsequently, type 2 diabetes in patients with CAH (2, 31, 32). Adult patients with CAH exhibit elevated fasting plasma glucose levels (31), reduced insulin sensitivity, and a β-cell response that is unable to compensate for insulin resistance (68). Significantly, insulin resistance in CAH seems to be related not only to the cumulative dose of glucocorticoids but also to the type of glucocorticoid used. Patients on long-term dexamethasone show a higher prevalence of insulin resistance compared to those taking prednisolone or hydrocortisone (8).

The impact of glucocorticoids on vascular function, particularly in the context of treatment adherence, remains poorly understood. Non-adherence to treatment in CAH has been correlated with detrimental effects on health, including greater intima–media thickness (69) and a poorer quality of life (70). Finkielstain et al. (32) emphasized the critical importance of consistent treatment adherence in modulating disease outcomes, further highlighting the urgent need for longitudinal investigations in this population.

Interestingly, the effects of systemic glucocorticoid therapy in CAH can also be influenced at the receptor level. Variations in the glucocorticoid receptor gene (NR3C1) may be associated with either negative or positive metabolic and cardiovascular profiles (71). For example, the A3669G polymorphism is linked to unfavorable lipid profiles in pediatric patients with CAH, while the ER22/23EK haplotype reduces glucocorticoid sensitivity, leading to a more favorable metabolic profile. In contrast, the N363S and BclI restriction fragment length polymorphisms increase glucocorticoid sensitivity, raising the risk of type 2 diabetes, obesity, and cardiovascular diseases (72, 73). BclI heterozygotes with CAH show higher body mass index (BMI), waist circumference, and systolic blood pressure compared to those with the wild-type (74), though this polymorphism is less common in patients with CAH than in the general population (71).

4 Assessment of endothelial function in CAH in vivo

The pivotal role of the endothelium in vascular-related diseases has driven increased scientific attention in examining the endothelial function as a tool for screening, as well as for monitoring the course of the diseases and evaluating treatment outcomes (75). Traditionally, endothelial function is evaluated through endothelium-dependent vasomotion, which can be measured in either the coronary or peripheral circulation. While invasive angiography is still considered the gold standard for measuring coronary endothelial function (76), there is no agreement on the gold standard for the measurement of peripheral endothelial function (77).

Well-established non-invasive techniques for evaluating peripheral endothelial function include strain-gauge venous occlusion forearm plethysmography (78, 79), flow-mediated dilation (FMD) (79, 80), peripheral arterial tonometry (PAT) (79), and laser Doppler flowmetry (79). Less conventional non-invasive techniques include pulse wave velocity (PWV) (81) and indirect endothelial assessment via intima-media thickness (IMT) measurement (82) (Table 1). Unlike invasive techniques, which are associated with risks such as vascular injury, infection, and procedural complications, non-invasive methods are inherently safer, cost-efficient, logistically simpler, and well-suited for implementation in both clinical practice and large-scale epidemiological studies. According to several studies, non-invasive assessment of peripheral vascular function may be useful in identifying patients at risk for cardiac adverse events, including cardiac death, myocardial infarction, revascularization, or hospitalization for cardiac causes (83).

4.1 Flow-mediated dilatation

One of the most used techniques to study endothelial function in vivo is FMD, which is assessed using ultrasound to measure changes in the diameter of the brachial artery in response to increased blood flow following a period of vascular occlusion created by a blood pressure cuff. This response is highly dependent on the availability of NO. Endothelial dysfunction is indicated by decreased vasodilation, as shown by lower FMD in the brachial artery.

The benefits of the FMD technique encompass cost-efficiency, non-invasiveness, accessibility, and the use of validated digital software for automated analyses. However, achieving optimal examination is technically demanding, and variations in techniques and protocols can impact the consistency and reliability of results. Moreover, factors such as diet, coffee consumption, medication, vitamins, physical activity, tobacco use, air temperature, and the menstrual cycle can influence a patient’s FMD, potentially introducing confounding variables into the study outcomes (28). Nonetheless, the brachial FMD method provides a validated, non-invasive evaluation of endothelial function (76).

Wierzbicka-Chmiel et al. (84) reported that 19 patients with CAH had decreased mean FMD compared with the control group. Farghaly et al. (16) showed that FMD was impaired in 40 patients with CAH and associated with elevated levels of neopterin and high sensitivity C-reactive protein (hs-CRP), the markers of vascular inflammation. According to Harrington et al. (85), impaired FMD was observed in a group of 14 adolescents with CAH, similar to obese control subjects. Given the limited number of studies assessing FMD in CAH, it is noteworthy that impaired FMD is a well-recognized indicator of endothelial dysfunction in other conditions associated with increased cardiovascular risk, such as type 2 diabetes (86–88), PCOS (89–91), obesity (92–94), heart failure (95), and peripheral artery disease (96).

4.2 Peripheral arterial tonometry

The PAT method, which is used in the EndoPAT device (Itamar Medical Inc., Caesarea, Israel), has emerged as a newer than FMD, non-invasive technology for measuring endothelial dysfunction. The device uses non-invasive pneumatic probes placed on both index fingers to measure pulsatile arterial volume changes at rest and during reactive hyperemia, which occurs in response to increased shear stress. A blood pressure cuff is placed over the brachial artery and inflated to occlude blood flow, and the response after deflation is recorded. The pulse wave amplitude (PWA) is measured, and the reactive hyperemia index (RHI) result is automatically calculated. The RHI is calculated as the ratio of the average PWA during the reactive phase to the average amplitude measured during the stabilization period. A suggested RHI threshold for indicating endothelial dysfunction is <1.67 (97–99). To adjust for systemic changes, this ratio is normalized using the concurrent signal from the contralateral finger. The EndoPAT device also assesses the peripheral augmentation index (AI), which measures arterial stiffness, calculated based on PWA.

The main advantages of PAT technology include its easy accessibility, operator independence, automated calculation, and control by the contralateral arm (83). PAT operators can be trained in a relatively short amount of time and do not require specialized certification. A major limitation is the unclear understanding of its pathophysiological basis (100). Unlike FMD, which evaluates macrovascular dilation, PAT assesses microvessel dilation. The endpoint measured by PAT, PWA, is thought to reflect arterial distensibility and venous capacitance in the digital vasculature, suggesting that changes in PWA may indicate vascular function. However, the structure of the digital vasculature is complex, comprising both nutritive vessels and arteriovenous anastomoses. The sympathetic nervous system primarily regulates the resting vascular tone in these vessels, with NO playing a minimal role (101). There are also concerns regarding the cutoff point for RHI, particularly in relation to age. Jujic et al. (102) postulated that an RHI result under 1.67, an early marker of endothelial dysfunction, may not be a suitable measure of endothelial function in individuals under 30 years of age. Their findings suggest that low RHI in young, healthy individuals may not necessarily indicate true endothelial dysfunction, but rather be an artefact of the limited ability of healthy arteries to dilate post-occlusion (102).

Available data on the positive predictive value (PPV) and negative predictive value (NPV) of the EndoPAT test are heterogeneous and vary depending on the studied population and clinical context. For instance, in the evaluation of erectile dysfunction, the PPV was relatively low at 43%, whereas the NPV reached 90%, indicating a greater utility in excluding rather than confirming organic endothelial dysfunction (103). In contrast, when EndoPAT was compared to the acetylcholine provocation test—the gold standard for diagnosing coronary endothelial dysfunction—the sensitivity was reported at 80% and specificity at 85%, supporting its potential role in identifying coronary artery spasm (99). These differences highlight the importance of interpreting EndoPAT results within the appropriate clinical framework.

Despite several limitations, numerous studies in both adult and pediatric literature reveal PAT’s satisfactory reproducibility and reliability (104–106). To date, no study utilizing PAT technology in individuals with CAH has been published. However, reduced RHI values have been reported in patients with other conditions associated with increased cardiovascular risk, including coronary artery disease (107), type 2 diabetes (108, 109), and metabolic syndrome (110). In contrast, the levels of RHI were consistent with preserved endothelial function in both groups of patients with PCOS, whether or not they had non-alcoholic fatty liver disease (NAFLD) (111).

4.3 Pulse wave velocity

PWV is the proposed gold standard for arterial stiffness and an indicator of early atherosclerosis (112), however, this technique can also be applied to studies of endothelial function (81). The predictive value of PWV for the occurrence of cardiovascular diseases has been demonstrated in both the general population and patients with various clinical conditions, including hypertension (113, 114), type 2 diabetes (115), end-stage renal disease (116), stroke (117), and coronary artery disease (118).

Measuring PWV involves the delay in the peak of the peripheral pulse wave, typically in relation to the QRS complex recorded simultaneously using electrocardiography. Increased vessel stiffness results in faster pulse wave propagation. The delay is determined by measurements taken at two different body sites, such as the carotid and femoral arteries (carotid-femoral PWV) or brachial and ankle arteries (brachial-ankle PWV). These two PWVs are most widely used in clinical and research fields. By selecting specific pulse wave recording points, it is possible to assess both central arterial stiffness and peripheral stiffness, independent of aortic condition. In endothelial studies, PWV measurements rely on the assumption that administering vasodilators isolates the contribution of vascular tone (119). PWV measurement is clinically beneficial due to its simplicity, non-invasive nature, cost-effectiveness, and reproducibility (120). Currently, no data are available on the PPV or NPV of PWV measurement in the assessment of endothelial function.

Costa et al. (121) did not observe any significant differences in PWV between 47 women with NCCAH and controls, nor across different therapy groups (dexamethasone vs. contraceptive pills). Similarly, Rosenbaum et al. (122) reported no significant differences in PWV values between 84 patients with CAH (both CCAH and NCCAH) and controls.

However, outside the CAH population, many studies have recently revealed an association between increased PWV and coronary atherosclerosis (123–125). In patients with PCOS, PWV measured at the brachial artery was found to be significantly elevated, although aortic PWV did not differ between the PCOS and control groups (126). Moreover, Wang et al. (127) reported that brachial-ankle PWV was associated with metabolic syndrome and increased progressively with the number of metabolic syndrome components in the general population.

4.4 Intima-media thickness

IMT is a measurement of the thickness of artery walls by ultrasound to detect the presence or track the progression of cardiovascular disease. In clinical practice, the IMT measurement is most commonly performed in the carotid arteries. A common carotid intima-media thickness (cIMT) measurement greater than 0.9 mm has been considered a significant factor influencing cardiovascular prognosis (128). Since increased IMT is a widely recognized sign of endothelial impairment (82) and a recognized indicator of atherosclerosis (129), which is closely linked to endothelial dysfunction, it can be used as an indirect measure of endothelial condition. Several studies have linked endothelial dysfunction with cIMT in patients with established atherosclerosis or coronary artery disease (130, 131). Consistently, endothelial dysfunction, defined as endothelium-dependent vasodilation (EDV) ≤4.5%, has been associated with a sensitivity of 71%, a specificity of 81%, and a PPV of 95% for the presence of coronary artery disease, further supporting the role of early vascular changes as markers of impaired endothelial function (130).

The exploration of IMT in relation to CAH has been the subject of multiple studies (60, 122, 132–138), with results varying significantly. Most of the studies (133–139) have reported notable differences in IMT between patients with CAH and controls, however, some research has shown normal IMT values, similar to those of control groups (60). The increase in cIMT is more pronounced in adults compared to youth (56), however, only three studies have examined adults (122, 133, 140), while the rest have focused on pediatric and adolescent populations (60, 134–140). Rosenbaum et al. (122) observed no significant difference between cIMT values in 84 adult patients with CAH and controls. Kim et al. (140) found that cIMT was associated with elevated androgen levels in 20 adolescents and young adults with CAH, with a loss of sex differences observed in female patients with excess androgen exposure. However, the subjects with CAH did not have significantly different cIMT values compared to controls. They also found that cIMT was significantly greater in obese than in non-obese individuals with CAH (140). Amr et al. (137) reported significantly higher CIMT in 32 children with CAH, without differences between the SV and SW forms of CCAH. Wasniewska et al. (138) observed increased IMT at different sites in 18 adolescents with CAH, with no differences between CCAH and NCCAH. Rodrigues et al. (136) has found remarkably higher values of cIMT in 40 patients with CAH, with no notable differences between those of normal weight and those who were overweight. Özdemir et al. (139) observed that 25 children with CAH exhibited higher IMT and decreased distensibility of the aorta and carotid arteries compared to control subjects, indicating the potential for early subclinical atherosclerosis. Akyürek et al. (134) observed that cIMT was higher in hypertensive compared to normotensive patients with CAH. Metwalley et al. (135) identified a significant correlation between cIMT and markers of disease management, including treatment duration and levels of 17-OHP and testosterone, indicating that elevated androgen levels may contribute to an increased risk of vascular dysfunction. Notably, cIMT showed no correlation with the hydrocortisone dose equivalent (135).

5 Novel biomarkers of endothelial function in CAH

A broad spectrum of potential biomarkers linked to endothelial function has been identified in reviews addressing cardiovascular diseases (11, 141, 142), renal diseases (143), and peripheral vascular diseases (144, 145). The most extensively studied include endothelial progenitor cells (146, 147), endothelial microparticles (148), microRNAs (149, 150), and adhesion molecules such as P-selectin (151), E-selectin (152), ICAM-1 (153), and VCAM-1 (153), along with molecules involved in the coagulation pathway, particularly von Willebrand factor (154). Although the levels of these well-characterized biomarkers have not yet been investigated in individuals with CAH, some data are available on less extensively studied or newly identified biomarkers, including neopterin (155), osteoprotegerin (132, 156), fetuin A (157), homocysteine (158, 159), leptin (42, 57, 160–163), adiponectin (60, 164), C-reactive protein (CRP) (55, 165), hsCRP (38, 57, 135), interleukin 6 (IL-6) (55, 57, 121, 166), and circulating endothelial cells (CECs) (135) (Table 2).

Although biomarkers hold significant promise, standardized chemistry tests and protocols for evaluating endothelial damage are not yet available and are currently limited to clinical research applications. It has been suggested that the most effective approach for assessing endothelial function could involve combining tests for circulating endothelial biomarkers with vasomotor response assessments (10). More recently, researchers have been exploring a multibiomarker strategy that integrates both traditional and novel circulating markers (168), offering a potentially more robust tool for cardiovascular risk stratification and therapy monitoring.

5.1 Neopterin

Neopterin, a metabolite of guanosine triphosphate (GTP), is synthesized by activated macrophages in response to stimulation by γ-interferon secreted by activated T-lymphocytes (169). Neopterin promotes atherothrombosis by increasing tissue factor-mRNA transcription and the expression of adhesion molecules ICAM-1 and VCAM-1 (170), however, it also suppresses TNF-α-induced expression of MCP-1, ICAM-1, and VCAM-1, reducing adhesion to endothelial cells, and inhibiting macrophage foam cell formation and smooth muscle cell proliferation (171). Neopterin levels correlate with ROS production and its toxic effects (172), making neopterin an indirect marker of oxidative stress during cell-mediated immune responses. Its vascular role in atherosclerotic processes, either beneficial or deleterious, is still under investigation.

Farghaly et al. (16) reported that patients with CAH had higher neopterin levels compared to healthy controls. These elevated neopterin levels were significantly associated with endothelial dysfunction, as demonstrated by brachial artery FMD measurements (16). Given the limited research on neopterin in CAH, it is relevant to note that increased plasma neopterin levels have also been observed in various other conditions characterized by vascular or systemic inflammation, including atherosclerosis (173, 174), coronary artery disease (175), hypertension (176), and ischemic stroke (177).

5.2 Osteoprotegerin

Osteoprotegerin is a member of the tumor necrosis factor (TNF) receptor superfamily, playing a crucial role in regulating bone metabolism (178). It is a glycoprotein that prevents the differentiation and activity of osteoclasts by binding to the receptor activator of nuclear factor-kappa B ligand (RANKL), thereby inhibiting RANKL from interacting with its receptor, RANK. This blockage of the RANK/RANKL pathway leads to decreased osteoclast formation and reduced survival and activation of mature osteoclasts (179, 180). Through these mechanisms, osteoprotegerin contributes to preserving the balance between bone resorption and formation (179). Additionally, TNF-related apoptosis-inducing ligand (TRAIL), another member of the TNF superfamily, also interacts with osteoprotegerin (181).

Apart from its role as a regulator of bone metabolism, osteoprotegerin has recently emerged as a significant factor in in the pathogenesis of atherosclerosis and cardiovascular diseases (182, 183), amplifying the adverse effects of inflammation and several traditional risk factors such as hyperlipidemia, type 2 diabetes, and hypertension (184). Furthermore, genetic studies have shown associations of osteoprotegerin gene polymorphisms with cardiovascular disease (185, 186). Notably, osteoprotegerin binds directly to RANKL, interfering with its interaction with the RANK receptor on the endothelium and thereby regulating vascular calcification (187, 188). It can act as a receptor for TRAIL, inhibiting the effects of TRAIL on the up-regulation of eNOS and down-regulation of ROS production. In addition, osteoprotegerin also activates the renin-angiotensin system and induces vascular endothelial growth factors, leading to inflammatory and fibrotic processes (189, 190). It has also been demonstrated to induce the expression of VCAM-1, ICAM-1, and E-selectin on endothelial cells, promoting leukocyte adhesion, which is an early step in endothelial cell dysfunction (191).

Although the link between osteoprotegerin concentration and cardiovascular risk in patients with CAH has not been evaluated yet, evidence suggests an association between osteoprotegerin and bone metabolism in people with CAH (132, 156, 167). It was found that osteoprotegerin levels were significantly higher in children with CAH compared to controls, indicating a compensatory mechanism against increased bone resorption in CAH (156). In contrast, another study showed that children with CAH had significantly lower serum osteoprotegerin levels (132), similar to a case report in which a lower serum osteoprotegerin level was found in a child with CAH (167).

Given the limited and inconsistent data on osteoprotegerin in CAH, insights from other conditions characterized by endothelial dysfunction may offer a broader perspective on the potential vascular implications of altered osteoprotegerin levels. Several studies have demonstrated a significant association between osteoprotegerin concentrations and endothelial dysfunction, particularly in patients with hyperuricemia (192), type 2 diabetes mellitus (193), and HIV infection (194). However, studies examining individuals with diabetes (195) or PCOS (196), have reported no correlation between osteoprotegerin levels and alterations in endothelial function.

5.3 Fetuin-A

Fetuin-A is a heterodimer plasma glycoprotein of the cystatin superfamily of protease inhibitors, predominantly expressed in the liver (197). It contributes to insulin resistance by binding to the tandem fibronectin type 3 domains in the extracellular β-subunit of the insulin receptor, inhibiting its activity in peripheral tissues. This binding occurs away from the α-subunits, where insulin binds, with both insulin and fetuin-A targeting the receptor’s ectodomain; however, while insulin activates the receptor’s intrinsic tyrosine kinase activity, fetuin-A deactivates it (198).

Increased fetuin-A levels are associated with various metabolic health factors such as insulin sensitivity (199), glucose tolerance (200), lipid concentrations (201), and inflammatory cytokine levels (202). However, fetuin-A plays an important role in preventing cardiovascular calcification by binding to small calcium-phosphate complexes, preventing their expansion, aggregation, and precipitation (203). It also promotes phagocytosis of extracellular vesicles and apoptotic cells by vascular smooth muscle cells and macrophages, which helps reduce both apoptosis and calcification in conditions with elevated extracellular mineral ion concentration in tissues (204).

Kurnaz et al. (157) observed elevated levels of fetuin-A in 56 patients with CCAH, compared to a control group, along with increased insulin levels and disrupted insulin signaling. Furthermore, the high levels of fetuin-A and insulin substances showed a positive correlation with free and total testosterone. The authors postulated that these findings could be linked to androgen excess and prolonged or high-dose glucocorticoid therapy in people with CAH (157). They suggested that the presence of androgen receptors in liver cells may allow excess androgens to stimulate the overproduction of fetuin-A and insulin, potentially contributing to insulin resistance (157, 205).

The potential involvement of fetuin-A in the metabolic disturbances observed in CAH is further supported by studies in other conditions characterized by insulin resistance and increased cardiometabolic risk. Higher circulating levels of fetuin-A have been linked to obesity (206) and its related conditions, including type 2 diabetes (207), metabolic syndrome (201, 206), PCOS (208) (209), and NAFLD (200). Liu et al. (208) observed that patients with PCOS had higher circulating fetuin-A levels compared to healthy women. Furthermore, higher fetuin-A levels correlated positively with BMI, waist-to-hip ratio, LDL cholesterol and triglyceride concentrations, and other indicators (208). Enli et al. (209) also observed higher fetuin-A levels in patients with PCOS, which correlated positively with insulin, the Homeostasis Model Assessment of Insulin Resistance (HOMA-IR), and the free androgen index.

5.4 Homocysteine

Homocysteine, an amino acid containing a sulfhydryl group, is an intermediate product in the metabolism of methionine and cysteine that affects many cellular biological processes, such as cellular methylation status, cell metabolism, and cell injury (210). Increased concentration of fasting plasma homocysteine (higher than 15 μmol/L) is defined as hyperhomocysteinemia (211), and is associated with various neurodegenerative, metabolic, and cardiovascular disorders (83, 212–218).

Hyperhomocysteinemia contributes to endothelial dysfunction through several mechanisms. First, it stimulates the overproduction of ROS, leading to oxidative stress, which impairs the bioavailability of NO and results in impaired blood vessel relaxation (219). Second, high homocysteine levels induce the release of pro-inflammatory cytokines and other inflammatory mediators, which contribute to the activation of endothelial cells and promote vascular inflammation (220). Lastly, hyperhomocysteine can impair the activity of eNOS (221).

Metwalley et al. (159) observed elevated homocysteine levels in 36 children with CAH, particularly among those with poor disease control. This elevation correlated with increased cIMT, left ventricular mass index, and mitral deceleration time, indicating a potential risk for subclinical atherosclerosis and left ventricular dysfunction (159). Krysiak et al. (222) found that the mean homocysteine concentration was significantly higher in patients with NCCAH compared to the control group. This difference remained significant after adjusting for age and BMI. In contrast, Falhammar et al. (158) reported lower homocysteine levels in male patients with CAH under 30 years of age compared to controls, suggesting a potential association with cardiovascular protection. However, it was proposed that the differing results could be attributed to variations in age, sample size, ethnicity, dietary habits, genetic factors, research methods, and the different steroid treatments (223). Bayraktar et al. found no statistically significant difference in mean homocysteine concentrations between 50 patients with CAH and the control group.

Beyond CAH, hyperhomocysteinemia has been widely studied in other conditions characterized by metabolic dysfunction and increased cardiovascular risk. Elevated serum homocysteine concentrations have been demonstrated in women with PCOS (224–226), in obese and overweight patients with hypertension, and in normotensive obese individuals (227). Furthermore, a study by Vaya et al. (228) reported that homocysteine levels in morbidly obese patients were associated with increased waist circumference and insulin resistance.

5.5 Leptin

Leptin is a pleiotropic hormone secreted by adipocytes that plays a role in various biological processes, such as angiogenesis, vascular function, inflammatory response, bone homeostasis, and reproduction (229). Increased serum leptin levels are directly associated with higher adipose tissue mass and are a significant contributor to obesity and its metabolic complications.

The reports on the role of leptin are contradictory in CAH. A study by Charmandari et al. (42) demonstrated significantly elevated leptin concentrations in 18 young patients (2–12 years old) with CCAH, compared to controls, regardless of BMI and sex. Leptin levels were inversely correlated with epinephrine and free metanephrine concentrations, suggesting a reduced inhibitory effect of catecholamines on leptin secretion (42). Additionally, the group with CAH exhibited a loss of gender dimorphism in leptin concentrations, possibly due to androgen excess in female patients (42). Increased leptin levels and strong correlations between leptin, obesity (32, 38, 60), and HOMA-IR (60) have been observed in studies including both patients with CCAH and NCCAH. Interestingly, Borges et al. (160) demonstrated significantly elevated leptin secretion, along with higher BMI and body fat percentage, exclusively in male patients with CAH compared to controls, while no differences were observed in female patients. In contrast, several studies have reported leptin concentrations in patients with CAH to be comparable to those of controls, despite higher BMI and body fat (57, 161–163). However, Volkl et al. (161) observed significantly lower concentrations of soluble leptin receptors in 51 individuals with CAH compared to the control group, suggesting an increased level of free (unbound) serum leptin.

In addition to findings in CAH, numerous studies have investigated the role of hyperleptinemia in cardiovascular diseases, including congestive heart failure, myocardial infarction, hypertension, and coronary artery disease (230, 231), highlighting its potential contribution to vascular dysfunction. It has been found that elevated plasma leptin levels are associated with coronary artery calcification (232) and with higher serum cholesterol, triglycerides, and CRP levels in patients with coronary artery disease (233). In contrast to these findings, several other studies have suggested that leptin may exert protective effects on blood vessels in obese individuals (234).

5.6 Adiponectin

Adiponectin, an adipokine secreted by adipocytes, is a well-known homeostatic factor that regulates glucose levels, lipid metabolism, and insulin sensitivity through its anti-inflammatory, anti-fibrotic, and antioxidant effects (235). In addition to adipocytes, adiponectin is also expressed in other tissues, including liver parenchyma cells (236), myocytes (237), and epithelial cells (238). The effects of adiponectin are primarily mediated through adiponectin receptors (AdipoR1 and AdipoR2) (239), and also via T-cadherin receptor (240). Adiponectin acts directly on the liver, skeletal muscle (239), and vasculature, including endothelial cells (241), smooth muscle cells (240), and pericytes (242).

Increasing evidence suggests that adiponectin plays a protective role in the cardiovascular system; it was found that adiponectin is inversely correlated with an increased cardiovascular risk, and hypo-adiponectinemia is associated with coronary artery disease and hypertension (243), left ventricular hypertrophy (244), and a greater risk of myocardial infarction (245). Furthermore, adiponectin is linked to the regulation of energy balance, enhanced angiogenesis, anti-inflammatory responses, antiapoptotic effects, and the prevention of interstitial fibrosis (246, 247). It protects the myocardium against oxidative stress and damage from ischemia/reperfusion, and it reduces cardiac remodeling caused by pressure overload or following a myocardial infarction (248, 249).

Adiponectin levels are known to be decreased in conditions such as obesity, insulin resistance, and type 2 diabetes (250), and the administration of glucocorticoids and androgens has been shown to reduce adiponectin levels (251, 252). However, the role of adiponectin in the cardiometabolic risk of patients with CAH remains unclear. Völkl et al. (164) reported higher adiponectin concentrations in 51 individuals with CAH compared to controls, regardless of sex, with no observed changes in serum leptin or the adiponectin/leptin ratio. Adiponectin levels were negatively correlated with BMI, serum dehydroepiandrosterone, and testosterone, but no clear relationship was found with hydrocortisone or fludrocortisone dosage (164). Similarly, Mooij et al. (60) observed a trend towards elevated adiponectin levels in 27 patients with CAH, compared to controls, which may suggest that adiponectin has a protective role in these patients.

5.7 Plasminogen activation inhibitor 1

Plasminogen activation inhibitor 1 (PAI-1) is the primary physiological inhibitor of urokinase plasminogen activator (u-PA) and tissue-plasminogen activator (tPA) and is a member of the serpin superfamily (serine proteinase inhibitors). Its most important function is to regulate plasminogen activator activity, thereby controlling plasmin formation. Consequently, PAI-1 plays a vital role in systemic homeostasis, contributing to the balance of the coagulation and fibrinolytic processes (253).

Data on PAI-1 levels in individuals with CAH and their relationship with cardiovascular and metabolic disorders are limited. Mooij et al. (55) found no significant differences in PAI-1 levels between patients with CAH and controls. Kim et al. (38) observed a positive correlation between PAI-1 levels and the amount of visceral and subcutaneous adipose tissue, both of which were higher in patients with CAH compared to controls. These findings suggest a potential link between PAI-1 and adverse metabolic profiles in CAH, although further research is needed to clarify its role in this population.

Evidence from other conditions shows that elevated PAI-1 levels are linked to the development of cardiovascular and metabolic disturbances, including atherosclerosis (254), type 2 diabetes, obesity, metabolic syndrome (255–257), and PCOS (258, 259). Moreover, increased levels of glucose (260), insulin (261) and its precursors (262), and free fatty acids (263) have been demonstrated to promote PAI-1 expression or to decrease the degradation rate of PAI-1 mRNA (264), further contributing to a prothrombotic and hypofibrinolytic state.

5.8 C-reactive protein

CRP is produced by the liver in response to inflammation and is regulated, in particular, by IL-6 and TNF-α. It is considered a prototypic marker of inflammation. CRP contributes to atherosclerosis by inducing pro-inflammatory signaling in monocytes and increasing cytokine production. In endothelial cells, it upregulates cell adhesion molecules, MCP-1, endothelin-1, and PAI-1, while decreasing prostacyclin release and tPA activity (265). Additionally, CRP has been shown to reduce eNOS activity and lower NO levels (165).

HsCRP is measured using high-sensitivity tests, which enable the detection of very low concentrations, making it valuable for assessing cardiovascular risk in seemingly healthy individuals. A body of evidence supports the utility of this marker in evaluating cardiovascular risk [reviewed by Ridker et al. (266)]. Nevertheless, although CRP has shown consistency as a cardiovascular risk biomarker across large prospective studies, with relative risk ratios approaching those of classical cardiovascular risk factors, its contribution to the current evaluation model of endothelial dysfunction remains minor (267).

Despite the clear impact of inflammation on the development of endothelial dysfunction, data on inflammatory markers in CAH are scarce. In a study of 40 adult patients with CAH, hsCRP levels were shown to be markedly elevated compared to controls, and they were even more pronounced in patients with poorly controlled disease (16). Similar findings have been reported in 32 children (135) and 21 adolescents (57) with CAH. Kim et al. (38) observed a positive correlation between hsCRP levels and the amount of visceral and subcutaneous adipose tissue in 28 adolescents and young adults with CAH. However, a Dutch study involving a cohort of 27 adult patients with CAH showed no differences in the levels of CRP or other inflammatory markers, such as IL-6 and IL-18, compared to healthy controls (55).

5.9 Interleukin 6

IL-6 is a pleiotropic cytokine involved in the regulation of immune responses by recruiting macrophages and lymphocytes to sites of injury or infection, acting as both a pro-inflammatory and anti-inflammatory agent. It also plays a role in a plethora of other functions, ranging from shaping the blood-brain barrier permeability to synovial inflammation, hematopoiesis, embryonic development, and vascular permeability (268–270). As IL-6 is involved in the development of autoimmunity and plays a crucial role in sepsis, targeting the IL-6 axis is an approved pharmacological option in a number of autoimmune disorders. IL-6 is synthesized locally at the inflammation site from where it is transported via the bloodstream and exerts its action on the liver, immune cells, and endothelium [reviewed by Tanaka et al. (271)]. In hepatocytes, its signaling leads to the synthesis of, in particular, CRP, serum amyloid A, antitrypsin, hepcidin, fibrinogen, thrombopoietin, and complement cascade elements (272). In the vessels, IL-6 not only acts directly on endothelial cells to increase the production of cytokines and chemokines, thereby activating the coagulation cascade, but also enhances vascular permeability by inducing VE-cadherin disassembly and promotes clot formation by stimulating tissue factor expression on monocytes (270). Moreover, IL-6 directly affects eNOS activity and increases vascular superoxide, which rapidly inactivates NO, thereby reducing NO bioavailability (273). IL-6 contributes to atherosclerosis by upregulating angiotensin II type 1 receptor expression (274), while increased binding of angiotensin II in turn increases IL-6 signaling (270, 275).

The unique role of IL-6 in shaping cardiovascular risk is demonstrated by experiments in mice with conditional overexpression of IL-6. These experiments demonstrated significantly impaired endothelium-dependent aortic relaxation, ROS formation in the aorta, and vascular dysfunction, all of which led to a markedly decreased survival rate (276). Due to its action on endothelial cells, IL-6 is considered both a marker of cardiovascular risk and a predictor of long-term cardiovascular mortality (277, 278).

According to Ariyawatkul et al. (57), IL-6 was unaltered in the cohort of 21 adolescents with CAH when compared to their healthy peers. Similarly, Delai et al. (166) found no significant differences in IL-6 levels between 31 patients with NCCAH and controls, suggesting that IL-6 may not directly contribute to insulin resistance in this population. Costa et al. (121) reported higher serum IL-6 levels in a group of 28 women with NCCAH treated with dexamethasone compared to 19 women treated with contraceptive pills. However, no statistically significant difference was found in IL-6 serum levels when comparing either group to the control group (121).

5.10 Circulating endothelial cells

CECs are mature, non-hematopoietic cells shed into the bloodstream following vascular injury or during normal endothelial turnover (279). Under physiological conditions, they are present in minimal numbers; however, elevated CEC counts have been documented across a variety of cardiovascular, oncological, and inflammatory diseases, underscoring their potential as sensitive biomarkers of endothelial damage. The enumeration and phenotyping of CECs—primarily via advanced multiparameter flow cytometry protocols—offer a non-invasive “liquid biopsy” approach to assess vascular health​ (280, 281). Unlike traditional endothelial markers, such as soluble adhesion molecules or von Willebrand factor, CECs directly reflect structural endothelial injury rather than secondary activation processes (282).

In a case-control study by Metwalley et al. (135), 32 children with CAH exhibited significantly higher CEC counts compared to healthy controls, alongside increased CA-IMT and elevated hsCRP levels. These findings support the presence of subclinical atherosclerosis and low-grade vascular inflammation in CAH. Moreover, CEC levels correlated positively with markers of androgen excess (testosterone, 17-OHP) and with measures of cardiac dysfunction, suggesting that chronic hormonal imbalance and insufficient disease control may exacerbate endothelial damage (135)​​.

The observed increase in CECs in CAH is consistent with findings from other clinical contexts, where elevated CEC counts have been established as markers of endothelial injury and disease severity. Increased CEC levels have been reported in cardiovascular conditions such as acute coronary syndromes (283), heart failure (284), and deep vein thrombosis (285). Similarly, increased CEC counts have been documented in patients with solid tumors (e.g., colorectal, breast, small-cell lung cancer) (286–288) and hematological malignancies such as multiple myeloma (289, 290), correlating with tumor progression and response to therapy​. Inflammatory and autoimmune diseases, including systemic lupus erythematosus (291, 292) and small-vessel vasculitis (293), are also associated with higher CEC counts, often indicating active disease and worse prognosis.

6 Omics-based tools in understanding endothelial dysfunctions

In parallel with classical biomarkers, omics-based technologies, including genomics, proteomics, and metabolomics, are emerging as powerful tools for the discovery of novel biomarkers of endothelial dysfunction, particularly relevant in CAH. Genomic studies have identified polymorphisms in genes regulating vascular tone, inflammation, and oxidative stress [reviewed by Kim et al. (294)], which may modify individual cardiovascular risk in CAH. Proteomic analyses facilitate the identification of endothelial-derived proteins associated with oxidative stress and vascular remodeling (295, 296), whereas metabolomics provides insights into metabolic alterations affecting endothelial health, including disruptions in arginine metabolism and lipid oxidation (297).

Although omics technologies have demonstrated great promise in various cardiovascular and metabolic diseases, their application to the assessment of endothelial function in patients with CAH has not yet been explored. Despite their advantages, such approaches remain primarily within the domain of scientific research. Their clinical implementation is currently limited by factors such as high costs, technical complexity, and the need for specialized equipment and expertise, which restrict their use to selected research centers. Consequently, omics-derived biomarkers are not routinely used in clinical practice, and further research and validation in well-characterized CAH cohorts are necessary before broader application can be considered.

7 Therapeutic strategies to enhance cardiovascular health in CAH

Current glucocorticoid replacement in CAH remains non-physiological, often leading to androgen excess or glucocorticoid overtreatment. To address these issues, new approaches aiming to replicate circadian cortisol rhythms have been developed, including modified-release hydrocortisone (MR-HC, Efmody/Chronocort), immediate-release tablets with a sustained-release core (SR-HC, Plenadren), and continuous subcutaneous hydrocortisone infusion.

MR-HC improves biochemical control of 17OHP but has shown inconsistent effects on blood pressure, fat mass, and glucose metabolism; early morning cortisol peaks may transiently worsen insulin sensitivity (298–300). Interestingly, a 6-month MR-HC therapy in patients with SW-CAH resulted in a reduction of plasma renin activity and an increase in sodium levels, suggesting more effective mineralocorticoid action, likely due to decreased concentrations of 17OHP, a known mineralocorticoid receptor antagonist (298). SR-HC, although effective in primary and secondary adrenal insufficiency, appears suboptimal in CAH due to insufficient pre-awakening cortisol rise and weak androgen suppression (301, 302). Continuous hydrocortisone infusion more closely mimics physiological cortisol rhythms and enables dose reduction; however, data on its metabolic effects are limited, and its clinical use will likely remain restricted to highly selected patients due to its complexity (303). Emerging therapeutic options, including CRF-1 antagonists (crinecerfont and tildacerfont), have shown potential to reduce adrenocorticotropic hormone (ACTH) and androgen levels, enabling possible glucocorticoid dose reduction, although their long-term impact remains to be established (304–306).

In parallel, adjunctive therapies aiming to counteract androgen excess, such as oral contraceptives or spironolactone, play a role in the management of CAH, although they introduce additional metabolic and cardiovascular concerns requiring careful consideration (307). Combined hormonal contraceptives have been associated with an increased risk of venous thromboembolism and hypertension (308), however, they may assist in regulating menstrual cycles and reducing androgenic symptoms in individuals with CAH. Spironolactone, commonly used in women with androgen excess, improves cardiovascular outcomes in various cardiac conditions. Nevertheless, its cardiometabolic safety in the context of androgen excess remains unestablished, and its use in CAH may be limited due to the frequent coexistence of aldosterone deficiency (309, 310).

Given the elevated cardiometabolic risk in patients with CAH, especially those predisposed to developing diabetes, interventions commonly used in the general population are considered applicable, although evidence specific to CAH remains limited. Intensive lifestyle modifications—encompassing dietary improvements, increased physical activity, smoking cessation, and weight management—are recommended as first-line measures (311). Isolated case reports have demonstrated the beneficial effects of metformin (312, 313), topiramate (314), and bariatric surgery (315, 316) on weight reduction, visceral fat mass, and insulin sensitivity in patients with CAH. Newer antiobesity medications (liraglutide, semaglutide, tirzepatide, and naltrexone/bupropion) have not yet been studied in patients with CAH.

Statin therapy is considered safe and effective for lipid management in CAH, demonstrating significant reductions in total and LDL cholesterol (317, 318) and potential antiandrogenic effects (318). Despite theoretical concerns regarding statin- and glucocorticoid-induced myopathy (319, 320), no such cases have been reported in CAH, likely due to the use of moderate doses.

Management of hypertension in CAH should prioritize angiotensin-converting enzyme (ACE) inhibitors and angiotensin-receptor blockers (ARBs) due to their cardioprotective properties, beneficial effects on endothelial function, and ability to improve insulin sensitivity (321, 322). Thiazide diuretics, β-blockers, and calcium channel blockers can be used as adjuncts, though β-blockers should preferably be third-generation agents (nebivolol, carvedilol) with more favorable metabolic profiles (311, 323, 324).

8 Conclusion

Endothelial dysfunction plays a critical role in the cardiovascular comorbidities observed in individuals with CAH due to 21OHD. The complex interplay of disease-related factors, such as androgen excess, metabolic disturbances, and glucocorticoid therapy, contribute to the heightened cardiovascular and metabolic risk in this population. The pathophysiological mechanisms driving endothelial dysfunction in CAH are multifaceted, involving oxidative stress, inflammation, and altered vascular tone. Although various diagnostic techniques—such as FMD, PAT, PWV, and IMT measurements—offer valuable insights into endothelial function, the optimal in vivo assessment method remains an area of ongoing investigation (Figure 3).

Figure 3

Emerging biomarkers of endothelial dysfunction, including neopterin, osteoprotegerin, fetuin-A, homocysteine, leptin, adiponectin, PAI-1, CRP, IL-6, and CECs, provide additional understanding of the pathophysiology of endothelial damage. Elevated levels of these biomarkers have been documented in populations with cardiovascular risk factors, indicating their potential for early detection and monitoring of endothelial dysfunction in CAH. Despite their promise, several limitations impede their translation into routine clinical practice. The lack of standardized chemical assay protocols for evaluating endothelial damage, high cost, and technical complexity restrict their current application to research settings primarily. Furthermore, many endothelial biomarkers exhibit limited sensitivity and specificity, often overlapping with markers of inflammation, platelet activation, and vascular smooth muscle dysfunction. Small sample sizes in clinical studies further constrain the reliability of these biomarkers, necessitating large-scale, multicenter trials to validate their clinical utility. Some findings remain controversial or inconclusive, highlighting the need for standardized approaches to address discrepancies in the literature. Additionally, the impact of metabolic and cardiovascular comorbidities on endothelial biomarkers remains insufficiently explored, particularly in the context of multiple coexisting conditions, which may have additive or interactive effects on biomarker levels.

Until stronger evidence becomes available, strategies for cardiovascular risk reduction in CAH should follow existing recommendations for high-risk populations, focusing on aggressive management of hypertension, dyslipidemia, disturbances in glucose metabolism, and obesity. Pharmacological strategies to improve cardiovascular health in CAH include optimized glucocorticoid replacement, adjunctive antiandrogen therapies, insulin sensitizers, statins, and renin–angiotensin system inhibitors, although disease-specific evidence remains limited.

Nevertheless, the present analysis is constrained by several important methodological limitations that warrant careful consideration. Most of the studies included in this review are observational, often retrospective in nature, and are limited by small sample sizes. Additionally, various sources of bias, such as sampling bias, recall bias, observation bias, and confounding bias, further weaken the strength of the available evidence and complicate the interpretation of findings related to endothelial dysfunction in CAH. Future research is needed to further investigate novel biomarkers of endothelial dysfunction and to refine diagnostic strategies, potentially integrating endothelial function assessment, to enhance cardiovascular risk evaluation and management. Particularly, well-designed, prospective studies conducted on large cohorts and across different age groups are necessary to better understand biomarker dynamics over time and their predictive value in clinical practice. Longitudinal cohort studies are needed to track changes in endothelial function over time and to evaluate the effects of factors such as age, treatment duration, and adherence to medical regimens. Moreover, the application of omics-based technologies holds promise for the discovery of novel endothelial biomarkers in CAH, potentially enhancing risk stratification and personalized management. Such efforts are crucial to improving long-term cardiovascular outcomes in individuals with CAH. Special attention to vascular health is essential for children with CAH, as atherosclerotic processes typically initiate in childhood and progress more rapidly in high-risk populations (80).

References

• 1

  Barbot M Mazzeo P Lazzara M Ceccato F Scaroni C . Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia. Front Endocrinol (Lausanne). (2022) 13:934675. doi: 10.3389/fendo.2022.934675

  • CrossRef
  • Google Scholar

• 2

  Falhammar H Frisen L Hirschberg AL Norrby C Almqvist C Nordenskjold A et al . Increased Cardiovascular and Metabolic Morbidity in Patients With 21-Hydroxylase Deficiency: A Swedish Population-Based National Cohort Study. J Clin Endocrinol Metab. (2015) 100:3520–8. doi: 10.1210/JC.2015-2093

  • CrossRef
  • Google Scholar

• 3

  Boulanger CM . Endothelium. Arterioscler Thromb Vasc Biol. (2016) 36:e26–31. doi: 10.1161/ATVBAHA.116.306940

  • CrossRef
  • Google Scholar

• 4

  Peyter AC Armengaud JB Guillot E Yzydorczyk C . Endothelial Progenitor Cells Dysfunctions and Cardiometabolic Disorders: From Mechanisms to Therapeutic Approaches. Int J Mol Sci. (2021) 22. doi: 10.3390/ijms22136667

  • CrossRef
  • Google Scholar

• 5

  Toma L Stancu CS Sima AV . Endothelial Dysfunction in Diabetes Is Aggravated by Glycated Lipoproteins; Novel Molecular Therapies. Biomedicines. (2020) 9. doi: 10.3390/biomedicines9010018

  • CrossRef
  • Google Scholar

• 6

  Torky A Sinaii N Jha S Desai J El-Maouche D Mallappa A et al . Cardiovascular Disease Risk Factors and Metabolic Morbidity in a Longitudinal Study of Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. (2021) 106:e5247–e57. doi: 10.1210/clinem/dgab133

  • CrossRef
  • Google Scholar

• 7

  Krysiak R Claahsen-van der Grinten HL Reisch N Touraine P Falhammar H . Cardiometabolic Aspects of Congenital Adrenal Hyperplasia. Endocr Rev. (2025) 46:80–148. doi: 10.1210/endrev/bnae026

  • CrossRef
  • Google Scholar

• 8

  Han TS Stimson RH Rees DA Krone N Willis DS Conway GS et al . Glucocorticoid treatment regimen and health outcomes in adults with congenital adrenal hyperplasia. Clin Endocrinol (Oxf). (2013) 78:197–203. doi: 10.1111/cen.2012.78.issue-2

  • CrossRef
  • Google Scholar

• 9

  Gallo G Volpe M Savoia C . Endothelial Dysfunction in Hypertension: Current Concepts and Clinical Implications. Front Med (Lausanne). (2021) 8:798958. doi: 10.3389/fmed.2021.798958

  • CrossRef
  • Google Scholar

• 10

  Deanfield JE Halcox JP Rabelink TJ . Endothelial function and dysfunction: testing and clinical relevance. Circulation. (2007) 115:1285–95. doi: 10.1161/CIRCULATIONAHA.106.652859

  • CrossRef
  • Google Scholar

• 11

  Gimbrone MA Jr. García-Cardeña G . Endothelial Cell Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. (2016) 118:620–36. doi: 10.1161/CIRCRESAHA.115.306301

  • CrossRef
  • Google Scholar

• 12

  Endemann DH Schiffrin EL . Endothelial dysfunction. J Am Soc Nephrol. (2004) 15:1983–92. doi: 10.1097/01.ASN.0000132474.50966.DA

  • CrossRef
  • Google Scholar

• 13

  Forstermann U Munzel T . Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation. (2006) 113:1708–14. doi: 10.1161/CIRCULATIONAHA.105.602532

  • CrossRef
  • Google Scholar

• 14

  Shaito A Thuan DTB Phu HT Nguyen THD Hasan H Halabi S et al . Herbal Medicine for Cardiovascular Diseases: Efficacy, Mechanisms, and Safety. Front Pharmacol. (2020) 11:422. doi: 10.3389/fphar.2020.00422

  • CrossRef
  • Google Scholar

• 15

  Xu S Ilyas I Little PJ Li H Kamato D Zheng X et al . Endothelial Dysfunction in Atherosclerotic Cardiovascular Diseases and Beyond: From Mechanism to Pharmacotherapies. Pharmacol Rev. (2021) 73:924–67. doi: 10.1124/pharmrev.120.000096

  • CrossRef
  • Google Scholar

• 16

  Farghaly HS Metwalley KA Raafat DM Saied GM Gabri MF Algowhary M . Association between vascular endothelial dysfunction and the inflammatory marker neopterin in patients with classic congenital adrenal hyperplasia. Atherosclerosis. (2021) 328:38–43. doi: 10.1016/j.atherosclerosis.2021.05.017

  • CrossRef
  • Google Scholar

• 17

  Steyers CM 3rd Miller FJ Jr . Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci. (2014) 15:11324–49. doi: 10.3390/ijms150711324

  • CrossRef
  • Google Scholar

• 18

  Shaito A Aramouni K Assaf R Parenti A Orekhov A Yazbi AE et al . Oxidative Stress-Induced Endothelial Dysfunction in Cardiovascular Diseases. Front Biosci (Landmark Ed). (2022) 27:105. doi: 10.31083/j.fbl2703105

  • CrossRef
  • Google Scholar

• 19

  Clarkson P Celermajer DS Powe AJ Donald AE Henry RM Deanfield JE . Endothelium-dependent dilatation is impaired in young healthy subjects with a family history of premature coronary disease. Circulation. (1997) 96:3378–83. doi: 10.1161/01.CIR.96.10.3378

  • CrossRef
  • Google Scholar

• 20

  Lundman P Eriksson MJ Stuhlinger M Cooke JP Hamsten A Tornvall P . Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginine. J Am Coll Cardiol. (2001) 38:111–6. doi: 10.1016/S0735-1097(01)01318-3

  • CrossRef
  • Google Scholar

• 21

  Ford MA McConnell JP Lavi S Rihal CS Prasad A Sandhu GS et al . Coronary artery endothelial dysfunction is positively correlated with low density lipoprotein and inversely correlated with high density lipoprotein subclass particles measured by nuclear magnetic resonance spectroscopy. Atherosclerosis. (2009) 207:111–5. doi: 10.1016/j.atherosclerosis.2009.04.039

  • CrossRef
  • Google Scholar

• 22

  Lavi S Prasad A Yang EH Mathew V Simari RD Rihal CS et al . Smoking is associated with epicardial coronary endothelial dysfunction and elevated white blood cell count in patients with chest pain and early coronary artery disease. Circulation. (2007) 115:2621–7. doi: 10.1161/CIRCULATIONAHA.106.641654

  • CrossRef
  • Google Scholar

• 23

  Shinozaki K Hirayama A Nishio Y Yoshida Y Ohtani T Okamura T et al . Coronary endothelial dysfunction in the insulin-resistant state is linked to abnormal pteridine metabolism and vascular oxidative stress. J Am Coll Cardiol. (2001) 38:1821–8. doi: 10.1016/S0735-1097(01)01659-X

  • CrossRef
  • Google Scholar

• 24

  Arcaro G Cretti A Balzano S Lechi A Muggeo M Bonora E et al . Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. (2002) 105:576–82. doi: 10.1161/hc0502.103333

  • CrossRef
  • Google Scholar

• 25

  Celermajer DS Sorensen KE Spiegelhalter DJ Georgakopoulos D Robinson J Deanfield JE . Aging is associated with endothelial dysfunction in healthy men years before the age-related decline in women. J Am Coll Cardiol. (1994) 24:471–6. doi: 10.1016/0735-1097(94)90305-0

  • CrossRef
  • Google Scholar

• 26

  Poredos P Kek A . Relation of blunted dilation of the brachial artery in insulin-dependent diabetes mellitus to microalbuminuria. Am J Cardiol. (2000) 86:364–7. doi: 10.1016/S0002-9149(00)00938-3

  • CrossRef
  • Google Scholar

• 27

  Falhammar H Frisén L Norrby C Hirschberg AL Almqvist C Nordenskjöld A et al . Increased Mortality in Patients With Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. (2014) 99:E2715–E21. doi: 10.1210/jc.2014-2957

  • CrossRef
  • Google Scholar

• 28

  Drera A Rodella L Brangi E Riccardi M Vizzardi E . Endothelial Dysfunction in Heart Failure: What Is Its Role? J Clin Med. (2024) 13. doi: 10.3390/jcm13092534

  • CrossRef
  • Google Scholar

• 29

  Swarup S Ahmed I Grigorova Y Zeltser R . Metabolic Syndrome. StatPearls. Treasure Island (FL: StatPearls Publishing Copyright © (2024).

  • Google Scholar

• 30

  Paizoni L Auer MK Schmidt H Hubner A Bidlingmaier M Reisch N . Effect of androgen excess and glucocorticoid exposure on metabolic risk profiles in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Steroid Biochem Mol Biol. (2020) 197:105540. doi: 10.1016/j.jsbmb.2019.105540

  • CrossRef
  • Google Scholar

• 31

  Arlt W Willis DS Wild SH Krone N Doherty EJ Hahner S et al . Health status of adults with congenital adrenal hyperplasia: a cohort study of 203 patients. J Clin Endocrinol Metab. (2010) 95:5110–21. doi: 10.1210/jc.2010-0917

  • CrossRef
  • Google Scholar

• 32

  Finkielstain GP Kim MS Sinaii N Nishitani M Van Ryzin C Hill SC et al . Clinical characteristics of a cohort of 244 patients with congenital adrenal hyperplasia. J Clin Endocrinol Metab. (2012) 97:4429–38. doi: 10.1210/jc.2012-2102

  • CrossRef
  • Google Scholar

• 33

  Bachelot A Plu-Bureau G Thibaud E Laborde K Pinto G Samara D et al . Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Horm Res. (2007) 67:268–76. doi: 10.1159/000098017

  • CrossRef
  • Google Scholar

• 34

  El-Maouche D Hannah-Shmouni F Mallappa A Hargreaves CJ Avila NA Merke DP . Adrenal morphology and associated comorbidities in congenital adrenal hyperplasia. Clin Endocrinol (Oxf). (2019) 91:247–55. doi: 10.1111/cen.2019.91.issue-2

  • CrossRef
  • Google Scholar

• 35

  Koenen M Hill MA Cohen P Sowers JR . Obesity, Adipose Tissue and Vascular Dysfunction. Circ Res. (2021) 128:951–68. doi: 10.1161/CIRCRESAHA.121.318093

  • CrossRef
  • Google Scholar

• 36

  Kajikawa M Higashi Y . Obesity and Endothelial Function. Biomedicines. (2022) 10. doi: 10.3390/biomedicines10071745

  • CrossRef
  • Google Scholar

• 37

  Higashi Y Noma K Yoshizumi M Kihara Y . Endothelial function and oxidative stress in cardiovascular diseases. Circ J. (2009) 73:411–8. doi: 10.1253/circj.CJ-08-1102

  • CrossRef
  • Google Scholar

• 38

  Kim MS Ryabets-Lienhard A Dao-Tran A Mittelman SD Gilsanz V Schrager SM et al . Increased Abdominal Adiposity in Adolescents and Young Adults With Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. (2015) 100:E1153–9. doi: 10.1210/jc.2014-4033

  • CrossRef
  • Google Scholar

• 39

  Deedwania PC . Metabolic syndrome and vascular disease: is nature or nurture leading the new epidemic of cardiovascular disease? Circulation. (2004) 109:2–4. doi: 10.1161/01.CIR.0000110642.73995.BF

  • CrossRef
  • Google Scholar

• 40

  Kim MS Ryabets-Lienhard A Bali B Lane CJ Park AH Hall S et al . Decreased adrenomedullary function in infants with classical congenital adrenal hyperplasia. J Clin Endocrinol Metab. (2014) 99:E1597–601. doi: 10.1210/jc.2014-1274

  • CrossRef
  • Google Scholar

• 41

  Merke DP Chrousos GP Eisenhofer G Weise M Keil MF Rogol AD et al . Adrenomedullary dysplasia and hypofunction in patients with classic 21-hydroxylase deficiency. N Engl J Med. (2000) 343:1362–8. doi: 10.1056/NEJM200011093431903

  • CrossRef
  • Google Scholar

• 42

  Charmandari E Weise M Bornstein SR Eisenhofer G Keil MF Chrousos GP et al . Children with classic congenital adrenal hyperplasia have elevated serum leptin concentrations and insulin resistance: potential clinical implications. J Clin Endocrinol Metab. (2002) 87:2114–20. doi: 10.1210/jcem.87.5.8456

  • CrossRef
  • Google Scholar

• 43

  Marra AM Improda N Capalbo D Salzano A Arcopinto M De Paulis A et al . Cardiovascular abnormalities and impaired exercise performance in adolescents with congenital adrenal hyperplasia. J Clin Endocrinol Metab. (2015) 100:644–52. doi: 10.1210/jc.2014-1805

  • CrossRef
  • Google Scholar

• 44

  Rosano GM Sheiban I Massaro R Pagnotta P Marazzi G Vitale C et al . Low testosterone levels are associated with coronary artery disease in male patients with angina. Int J Impot Res. (2007) 19:176–82. doi: 10.1038/sj.ijir.3901504

  • CrossRef
  • Google Scholar

• 45

  Metwalley KA Farghaly HS Abdelhamid A . Epicardial Fat Thickness in Children with Classic Congenital Adrenal Hyperplasia. J Clin Res Pediatr Endocrinol. (2019) 11:61–9. doi: 10.4274/jcrpe.galenos.2018.2018.0153

  • CrossRef
  • Google Scholar

• 46

  Zhang HJ Yang J Zhang MN Liu CQ Xu M Li XJ et al . Metabolic disorders in newly diagnosed young adult female patients with simple virilizing 21-hydroxylase deficiency. Endocrine. (2010) 38:260–5. doi: 10.1007/s12020-010-9382-9

  • CrossRef
  • Google Scholar

• 47

  Janus D Wojcik M Tyrawa K Janeczko M Bik-Multanowski M Starzyk JB . Intima media thickness of common carotids and abdominal aorta in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency in relation to their genotypes. Neuro Endocrinol Lett. (2017) 38:154–62.

  • Google Scholar

• 48

  Berbrier DE Leone CA Adler TE Bender JR Taylor HS Stachenfeld NS et al . Effects of androgen excess and body mass index on endothelial function in women with polycystic ovary syndrome. J Appl Physiol (1985). (2023) 134:868–78. doi: 10.1152/japplphysiol.00583.2022

  • CrossRef
  • Google Scholar

• 49

  Paradisi G Steinberg HO Hempfling A Cronin J Hook G Shepard MK et al . Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation. (2001) 103:1410–5. doi: 10.1161/01.CIR.103.10.1410

  • CrossRef
  • Google Scholar

• 50

  Improda N Barbieri F Ciccarelli GP Capalbo D Salerno M . Cardiovascular Health in Children and Adolescents With Congenital Adrenal Hyperplasia Due to 21-Hydroxilase Deficiency. Front Endocrinol (Lausanne). (2019) 10:212. doi: 10.3389/fendo.2019.00212

  • CrossRef
  • Google Scholar

• 51

  Kim MS Fraga NR Minaeian N Geffner ME . Components of Metabolic Syndrome in Youth With Classical Congenital Adrenal Hyperplasia. Front Endocrinol (Lausanne). (2022) 13:848274. doi: 10.3389/fendo.2022.848274

  • CrossRef
  • Google Scholar

• 52

  Ambrosino P Bachetti T D’Anna SE Galloway B Bianco A D’Agnano V et al . Mechanisms and Clinical Implications of Endothelial Dysfunction in Arterial Hypertension. J Cardiovasc Dev Dis. (2022) 9. doi: 10.3390/jcdd9050136

  • CrossRef
  • Google Scholar

• 53

  Barbot M Ceccato F Scaroni C . The Pathophysiology and Treatment of Hypertension in Patients With Cushing’s Syndrome. Front Endocrinol (Lausanne). (2019) 10:321. doi: 10.3389/fendo.2019.00321

  • CrossRef
  • Google Scholar

• 54

  Maccabee-Ryaboy N Thomas W Kyllo J Lteif A Petryk A Gonzalez-Bolanos MT et al . Hypertension in children with congenital adrenal hyperplasia. Clin Endocrinol (Oxf). (2016) 85:528–34. doi: 10.1111/cen.2016.85.issue-4

  • CrossRef
  • Google Scholar

• 55

  Mooij CF Kroese JM Sweep FC Hermus AR Tack CJ . Adult patients with congenital adrenal hyperplasia have elevated blood pressure but otherwise a normal cardiovascular risk profile. PLoS One. (2011) 6:e24204. doi: 10.1371/journal.pone.0024204

  • CrossRef
  • Google Scholar

• 56

  Tamhane S Rodriguez-Gutierrez R Iqbal AM Prokop LJ Bancos I Speiser PW et al . Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. (2018) 103:4097–103. doi: 10.1210/jc.2018-01862

  • CrossRef
  • Google Scholar

• 57

  Ariyawatkul K Tepmongkol S Aroonparkmongkol S Sahakitrungruang T . Cardio-metabolic risk factors in youth with classical 21-hydroxylase deficiency. Eur J Pediatr. (2017) 176:537–45. doi: 10.1007/s00431-017-2875-2

  • CrossRef
  • Google Scholar

• 58

  Vijayan R Bhavani N Pavithran PV Nair V Menon UV Menon AS et al . Metabolic profile, cardiovascular risk factors and health-related quality of life in children, adolescents and young adults with congenital adrenal hyperplasia. J Pediatr Endocrinol Metab. (2019) 32:871–7. doi: 10.1515/jpem-2019-0079

  • CrossRef
  • Google Scholar

• 59

  Roche EF Charmandari E Dattani MT Hindmarsh PC . Blood pressure in children and adolescents with congenital adrenal hyperplasia (21-hydroxylase deficiency): a preliminary report. Clin Endocrinol (Oxf). (2003) 58:589–96. doi: 10.1046/j.1365-2265.2003.01757.x

  • CrossRef
  • Google Scholar

• 60

  Mooij CF van Herwaarden AE Sweep F Roeleveld N de Korte CL Kapusta L et al . Cardiovascular and metabolic risk in pediatric patients with congenital adrenal hyperplasia due to 21 hydroxylase deficiency. J Pediatr Endocrinol Metab. (2017) 30:957–66. doi: 10.1515/jpem-2017-0068

  • CrossRef
  • Google Scholar

• 61

  Voülkl TMK Simm D Doütsch JR Rascher W Doürr HG . Altered 24-Hour Blood Pressure Profiles in Children and Adolescents with Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency. J Clin Endocrinol Metab. (2006) 91:4888–95. doi: 10.1210/jc.2006-1069

  • CrossRef
  • Google Scholar

• 62

  Hoepffner W Herrmann A Willgerodt H Keller E . Blood Pressure in Patients with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. J Pediatr Endocrinol Metab. (2006) 19:705–12. doi: 10.1515/JPEM.2006.19.5.705

  • CrossRef
  • Google Scholar

• 63

  Subbarayan A Dattani MT Peters CJ Hindmarsh PC . Cardiovascular risk factors in children and adolescents with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Clin Endocrinol (Oxf). (2014) 80:471–7. doi: 10.1111/cen.2014.80.issue-4

  • CrossRef
  • Google Scholar

• 64

  Bonfig W Roehl FW Riedl S Dorr HG Bettendorf M Bramswig J et al . Blood Pressure in a Large Cohort of Children and Adolescents With Classic Adrenal Hyperplasia (CAH) Due to 21-Hydroxylase Deficiency. Am J Hypertens. (2016) 29:266–72. doi: 10.1093/ajh/hpv087

  • CrossRef
  • Google Scholar

• 65

  El-Maouche D Arlt W Merke DP . Congenital adrenal hyperplasia. Lancet. (2017) 390:2194–210. doi: 10.1016/S0140-6736(17)31431-9

  • CrossRef
  • Google Scholar

• 66

  Han TS Walker BR Arlt W Ross RJ . Treatment and health outcomes in adults with congenital adrenal hyperplasia. Nat Rev Endocrinol. (2014) 10:115–24. doi: 10.1038/nrendo.2013.239

  • CrossRef
  • Google Scholar

• 67

  Speiser PW Azziz R Baskin LS Ghizzoni L Hensle TW Merke DP et al . Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. (2010) 95:4133–60. doi: 10.1210/jc.2009-2631

  • CrossRef
  • Google Scholar

• 68

  de Oliveira DM Tura A Vasques ACJ Camilo DF Lima MM de Lemos-Marini SHV et al . Insulin Resistance in Congenital Adrenal Hyperplasia is Compensated for by Reduced Insulin Clearance. J Clin Endocrinol Metab. (2021) 106:e1574–e85. doi: 10.1210/clinem/dgab010

  • CrossRef
  • Google Scholar

• 69

  Mnif MF Kamoun M Mnif F Charfi N Kallel N Ben Naceur B et al . Long-term outcome of patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Am J Med Sci. (2012) 344:363–73. doi: 10.1097/MAJ.0b013e31824369e4

  • CrossRef
  • Google Scholar

• 70

  Ekbom K Strandqvist A Lajic S Hirschberg A Falhammar H Nordenström A . The impact of adherence and therapy regimens on quality of life in patients with congenital adrenal hyperplasia. Clin Endocrinol (Oxf). (2022) 96:666–79. doi: 10.1111/cen.14676

  • CrossRef
  • Google Scholar

• 71

  Villela TR Barra CB Belisario AR Luizon MR Simoes ESAC Silva IN . Glucocorticoid receptor Gene (NR3C1) Polymorphisms and Haplotypes in patients with congenital adrenal hyperplasia. Mol Cell Endocrinol. (2021) 536:111399. doi: 10.1016/j.mce.2021.111399

  • CrossRef
  • Google Scholar

• 72

  Lin RC Wang XL Morris BJ . Association of coronary artery disease with glucocorticoid receptor N363S variant. Hypertension. (2003) 41:404–7. doi: 10.1161/01.HYP.0000055342.40301.DC

  • CrossRef
  • Google Scholar

• 73

  Roussel R Reis AF Dubois-Laforgue D Bellanne-Chantelot C Timsit J Velho G . The N363S polymorphism in the glucocorticoid receptor gene is associated with overweight in subjects with type 2 diabetes mellitus. Clin Endocrinol (Oxf). (2003) 59:237–41. doi: 10.1046/j.1365-2265.2003.01831.x

  • CrossRef
  • Google Scholar

• 74

  Moreira RP Bachega TA Machado MC Mendonca BB Bronstein MD Villares Fragoso MC . Modulatory effect of BclI GR gene polymorphisms on the obesity phenotype in Brazilian patients with Cushing’s disease. Clinics (Sao Paulo). (2013) 68:579–85. doi: 10.6061/clinics/2013(05)01

  • CrossRef
  • Google Scholar

• 75

  Musz P Podhajski P Grzelakowska K Umińska J . Non-invasive assessment of endothelial function — a review of available methods. Med Res J. (2021) 6:53–8. doi: 10.5603/MRJ.a2021.0008

  • CrossRef
  • Google Scholar

• 76

  Minhas AS Goerlich E Corretti MC Arbab-Zadeh A Kelle S Leucker T et al . Imaging Assessment of Endothelial Function: An Index of Cardiovascular Health. Front Cardiovasc Med. (2022) 9:778762. doi: 10.3389/fcvm.2022.778762

  • CrossRef
  • Google Scholar

• 77

  Anderson TJ . Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk. Can J Cardiol. (2006) 22 Suppl B:72B–80B. doi: 10.1016/S0828-282X(06)70990-4

  • CrossRef
  • Google Scholar

• 78

  Joannides R Bellien J Thuillez C . Clinical methods for the evaluation of endothelial function– a focus on resistance arteries. Fundam Clin Pharmacol. (2006) 20:311–20. doi: 10.1111/j.1472-8206.2006.00406.x

  • CrossRef
  • Google Scholar

• 79

  Lekakis J Abraham P Balbarini A Blann A Boulanger CM Cockcroft J et al . Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation. Eur J Cardiovasc Prev Rehabil. (2011) 18:775–89. doi: 10.1177/1741826711398179

  • CrossRef
  • Google Scholar

• 80

  Celermajer DS Sorensen KE Gooch VM Spiegelhalter DJ Miller OI Sullivan ID et al . Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. (1992) 340:1111–5. doi: 10.1016/0140-6736(92)93147-F

  • CrossRef
  • Google Scholar

• 81

  McEniery CM Wallace S Mackenzie IS McDonnell B Yasmin Newby DE et al . Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension. (2006) 48:602–8. doi: 10.1161/01.HYP.0000239206.64270.5f

  • CrossRef
  • Google Scholar

• 82

  Perrone-Filardi P Coca A Galderisi M Paolillo S Alpendurada F de Simone G et al . Noninvasive cardiovascular imaging for evaluating subclinical target organ damage in hypertensive patients: a consensus article from the European Association of Cardiovascular Imaging, the European Society of Cardiology Council on Hypertension and the European Society of Hypertension. J Hypertens. (2017) 35:1727–41. doi: 10.1097/HJH.0000000000001396

  • CrossRef
  • Google Scholar

• 83

  Rubinshtein R Kuvin JT Soffler M Lennon RJ Lavi S Nelson RE et al . Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events. Eur Heart J. (2010) 31:1142–8. doi: 10.1093/eurheartj/ehq010

  • CrossRef
  • Google Scholar

• 84

  Wierzbicka-Chmiel J Chmiel A Rychlik S Ogrodowczyk-Bobik M Marek B Kajdaniuk D . Vascular and cardiac function in young adults with classical congenital adrenal hyperplasia. Endokrynol Pol. (2017) 68:505–11. doi: 10.5603/EP.a2017.0046

  • CrossRef
  • Google Scholar

• 85

  Harrington J Pena AS Gent R Hirte C Couper J . Adolescents with congenital adrenal hyperplasia because of 21-hydroxylase deficiency have vascular dysfunction. Clin Endocrinol (Oxf). (2012) 76:837–42. doi: 10.1111/j.1365-2265.2011.04309.x

  • CrossRef
  • Google Scholar

• 86

  Cutruzzolà A Parise M Cacia M Lucà S Irace C Gnasso A . The relationship between endothelial-dependent flow-mediated dilation and diastolic function in type 2 diabetes. Acta Diabetologica. (2024) 61:1475–82. doi: 10.1007/s00592-024-02313-1

  • CrossRef
  • Google Scholar

• 87

  Ito H Nakashima M Meguro K Furukawa H Yamashita H Takaki A et al . Flow Mediated Dilatation Is Reduced with the Progressive Stages of Glomerular Filtration Rate and Albuminuria in Type 2 Diabetic Patients without Coronary Heart Disease. J Diabetes Res. (2015) 2015:728127. doi: 10.1155/2015/728127

  • CrossRef
  • Google Scholar

• 88

  Pillay S Anderson J Couper J Maftei O Gent R Pena AS . Children With Type 1 Diabetes Have Delayed Flow-Mediated Dilation. Can J Diabetes. (2018) 42:276–80. doi: 10.1016/j.jcjd.2017.06.011

  • CrossRef
  • Google Scholar

• 89

  Soyman Z Noyan V Tulmac M Yucel A Sagsoz N Bayrak T et al . Serum paraoxonase 1 activity, asymmetric dimethylarginine levels, and brachial artery flow-mediated dilatation in women with polycystic ovary syndrome. Fertil Steril. (2011) 95:1067–72. doi: 10.1016/j.fertnstert.2010.12.011

  • CrossRef
  • Google Scholar

• 90

  Pepene CE . Evidence for visfatin as an independent predictor of endothelial dysfunction in polycystic ovary syndrome. Clin Endocrinol (Oxf). (2012) 76:119–25. doi: 10.1111/j.1365-2265.2011.04171.x

  • CrossRef
  • Google Scholar

• 91

  Alexandraki K Protogerou AD Papaioannou TG Piperi C Mastorakos G Lekakis J et al . Early microvascular and macrovascular dysfunction is not accompanied by structural arterial injury in polycystic ovary syndrome. Hormones (Athens). (2006) 5:126–36. doi: 10.14310/horm.2002.11176

  • CrossRef
  • Google Scholar

• 92

  Hussid MF Jordão CP Lopes-Vicente WR Virmondes L Cepeda F Katayama K et al . Flow-Mediated Dilation in Obese Adolescents: Correlation with Waist Circumference and Systolic Blood Pressure. FASEB J. (2018) 32:713.7–.7. doi: 10.1096/fasebj.2018.32.1_supplement.713.7

  • CrossRef
  • Google Scholar

• 93

  Mori Y . Flow-Mediated Dilatation in Obese Children. Clin Pediatr Endocrinology. (2003) 12:43–8. doi: 10.1297/cpe.12.43

  • CrossRef
  • Google Scholar

• 94

  Hashimoto M Akishita M Eto M Kozaki K Ako J Sugimoto N et al . The impairment of flow-mediated vasodilatation in obese men with visceral fat accumulation. Int J Obes Relat Metab Disord. (1998) 22:477–84. doi: 10.1038/sj.ijo.0800620

  • CrossRef
  • Google Scholar

• 95

  Premer C Blum A Bellio MA Schulman IH Hurwitz BE Parker M et al . Allogeneic Mesenchymal Stem Cells Restore Endothelial Function in Heart Failure by Stimulating Endothelial Progenitor Cells. EBioMedicine. (2015) 2:467–75. doi: 10.1016/j.ebiom.2015.03.020

  • CrossRef
  • Google Scholar

• 96

  Gokce N Keaney JF Jr. Hunter LM Watkins MT Nedeljkovic ZS Menzoian JO et al . Predictive value of noninvasively determined endothelial dysfunction for long-term cardiovascular events in patients with peripheral vascular disease. J Am Coll Cardiol. (2003) 41:1769–75. doi: 10.1016/S0735-1097(03)00333-4

  • CrossRef
  • Google Scholar

• 97

  Heffernan KS Patvardhan EA Kapur NK Karas RH Kuvin JT . Peripheral augmentation index as a biomarker of vascular aging: an invasive hemodynamics approach. Eur J Appl Physiol. (2012) 112:2871–9. doi: 10.1007/s00421-011-2255-y

  • CrossRef
  • Google Scholar

• 98

  Tanaka A Tomiyama H Maruhashi T Matsuzawa Y Miyoshi T Kabutoya T et al . Physiological Diagnostic Criteria for Vascular Failure. Hypertension. (2018) 72:1060–71. doi: 10.1161/HYPERTENSIONAHA.118.11554

  • CrossRef
  • Google Scholar

• 99

  Bonetti PO Pumper GM Higano ST Holmes DR Jr. Kuvin JT Lerman A . Noninvasive identification of patients with early coronary atherosclerosis by assessment of digital reactive hyperemia. J Am Coll Cardiol. (2004) 44:2137–41. doi: 10.1016/j.jacc.2004.08.062

  • CrossRef
  • Google Scholar

• 100

  Bruno RM Gori T Ghiadoni L . Endothelial function testing and cardiovascular disease: focus on peripheral arterial tonometry. Vasc Health Risk Manage. (2014) 10:577–84. doi: 10.2147/VHRM.S44471

  • CrossRef
  • Google Scholar

• 101

  Coffman JD . Effects of endothelium-derived nitric oxide on skin and digital blood flow in humans. Am J Physiol. (1994) 267:H2087–90. doi: 10.1152/ajpheart.1994.267.6.H2087

  • CrossRef
  • Google Scholar

• 102

  Jujic A Kenneback C Johansson M Nilsson PM Holm H . The impact of age on endothelial dysfunction measured by peripheral arterial tonometry in a healthy population-based cohort - the Malmo offspring study. Blood Press. (2023) 32:2234059. doi: 10.1080/08037051.2023.2234059

  • CrossRef
  • Google Scholar

• 103

  Bahouth Z Zreik R Graif A Nativ O Halachmi S Pillar G . Endothelial Function Assessment in Patients with Erectile Dysfunction. Isr Med Assoc J. (2015) 17:682–6.

  • Google Scholar

• 104

  Moerland M Kales AJ Schrier L van Dongen MG Bradnock D Burggraaf J . Evaluation of the EndoPAT as a Tool to Assess Endothelial Function. Int J Vasc Med. (2012) 2012:904141. doi: 10.1155/2012/904141

  • CrossRef
  • Google Scholar

• 105

  Fatihoglu SG Jam F Okutucu S Oto A . Noninvasive Investigation of the Presence and Extent of Coronary Artery Disease by the Evaluation of Fingertip-Reactive Hyperemia. Med Princ Pract. (2022) 31:262–8. doi: 10.1159/000522098

  • CrossRef
  • Google Scholar

• 106

  Selamet Tierney ES Newburger JW Gauvreau K Geva J Coogan E Colan SD et al . Endothelial pulse amplitude testing: feasibility and reproducibility in adolescents. J Pediatr. (2009) 154:901–5. doi: 10.1016/j.jpeds.2008.12.028

  • CrossRef
  • Google Scholar

• 107

  Heffernan KS Karas RH Patvardhan EA Jafri H Kuvin JT . Peripheral arterial tonometry for risk stratification in men with coronary artery disease. Clin Cardiol. (2010) 33:94–8. doi: 10.1002/clc.20705

  • CrossRef
  • Google Scholar

• 108

  Lal A Kazi S Kovoor P Liew G Mitchell P Thiagalingam A . Assessing endothelial function in type-2-diabetes using a novel method of ECG-gated retinal artery flicker provocation and digital reactive hyperaemia (Endopat&xae);. Heart Lung Circ. (2015) 24:S325. doi: 10.1016/j.hlc.2015.06.500

  • CrossRef
  • Google Scholar

• 109

  Lal A Thiagalingam A Mitchell P Gibbs O Barry T Kovoor P . PM417 Assessing endothelial function in type-2-diabetes mellitus using ECG-gated retinal artery flicker provocation and digital reactive hyperaemia (Endopat^®). Global Heart. (2014) 9:e146. doi: 10.1016/j.gheart.2014.03.1748

  • CrossRef
  • Google Scholar

• 110

  Zhang H Sun T Cheng Y Zhang J Zhang H Krittanawong C et al . Impact of metabolic syndrome and systemic inflammation on endothelial function in postmenopausal women. Turk Kardiyol Dern Ars. (2022) 50:57–65. doi: 10.5543/tkda.2022.47443

  • CrossRef
  • Google Scholar

• 111

  Dawson AJ Sathyapalan T Smithson JA Vince RV Coady AM Ajjan R et al . A comparison of cardiovascular risk indices in patients with polycystic ovary syndrome with and without coexisting nonalcoholic fatty liver disease. Clin Endocrinol (Oxf). (2014) 80:843–9. doi: 10.1111/cen.2014.80.issue-6

  • CrossRef
  • Google Scholar

• 112

  Laurent S Cockcroft J Van Bortel L Boutouyrie P Giannattasio C Hayoz D et al . Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J. (2006) 27:2588–605. doi: 10.1093/eurheartj/ehl254

  • CrossRef
  • Google Scholar

• 113

  Laurent S Katsahian S Fassot C Tropeano AI Gautier I Laloux B et al . Aortic stiffness is an independent predictor of fatal stroke in essential hypertension. Stroke. (2003) 34:1203–6. doi: 10.1161/01.STR.0000065428.03209.64

  • CrossRef
  • Google Scholar

• 114

  Boutouyrie P Tropeano AI Asmar R Gautier I Benetos A Lacolley P et al . Aortic stiffness is an independent predictor of primary coronary events in hypertensive patients: a longitudinal study. Hypertension. (2002) 39:10–5. doi: 10.1161/hy0102.099031

  • CrossRef
  • Google Scholar

• 115

  Cruickshank K Riste L Anderson SG Wright JS Dunn G Gosling RG . Aortic pulse-wave velocity and its relationship to mortality in diabetes and glucose intolerance: an integrated index of vascular function? Circulation. (2002) 106:2085–90. doi: 10.1161/01.CIR.0000033824.02722.F7

  • CrossRef
  • Google Scholar

• 116

  Blacher J Guerin AP Pannier B Marchais SJ Safar ME London GM . Impact of aortic stiffness on survival in end-stage renal disease. Circulation. (1999) 99:2434–9. doi: 10.1161/01.CIR.99.18.2434

  • CrossRef
  • Google Scholar

• 117

  Gasecki D Rojek A Kwarciany M Kowalczyk K Boutouyrie P Nyka W et al . Pulse wave velocity is associated with early clinical outcome after ischemic stroke. Atherosclerosis. (2012) 225:348–52. doi: 10.1016/j.atherosclerosis.2012.09.024

  • CrossRef
  • Google Scholar

• 118

  Ki YJ Choi DH Lee YM Lim L Song H Koh YY . Predictive value of brachial-ankle pulse wave velocity for long-term clinical outcomes after percutaneous coronary intervention in a Korean cohort. Int J Cardiol. (2014) 175:554–9. doi: 10.1016/j.ijcard.2014.06.032

  • CrossRef
  • Google Scholar

• 119

  Musz P Podhajski P Grzelakowska K Umińska J . Non-invasive assessment of endothelial function – a review of available methods. Med Res J. (2021) 6:53–8. doi: 10.5603/MRJ.a2021.0008

  • CrossRef
  • Google Scholar

• 120

  Munakata M . Brachial-ankle pulse wave velocity in the measurement of arterial stiffness: recent evidence and clinical applications. Curr Hypertens Rev. (2014) 10:49–57. doi: 10.2174/157340211001141111160957

  • CrossRef
  • Google Scholar

• 121

  Costa FC Gomes LG de Lima TM Bortolotto LA Hong V Verardino R et al . Cardiovascular risk in women with nonclassical congenital adrenal hyperplasia. J Clin Endocrinol Metab. (2024) 110(1):e72–9. doi: 10.1210/clinem/dgae155

  • CrossRef
  • Google Scholar

• 122

  Rosenbaum D Gallo A Lethielleux G Bruckert E Levy BI Tanguy ML et al . Early central blood pressure elevation in adult patients with 21-hydroxylase deficiency. J Hypertens. (2019) 37:175–81. doi: 10.1097/HJH.0000000000001850

  • CrossRef
  • Google Scholar

• 123

  Bechlioulis A Vakalis K Naka KK Bourantas CV Papamichael ND Kotsia A et al . Increased aortic pulse wave velocity is associated with the presence of angiographic coronary artery disease in overweight and obese patients. Am J Hypertens. (2013) 26:265–70. doi: 10.1093/ajh/hps039

  • CrossRef
  • Google Scholar

• 124

  Duman OO Goldeli O Gursul E Baris N Ozpelit E Simsek MA . The value of aortic pulse wave velocity in predicting coronary artery disease diagnosis and severity. Acta Cardiol. (2015) 70:315–22. doi: 10.1080/ac.70.3.3080636

  • CrossRef
  • Google Scholar

• 125

  Braber TL Prakken NH Mosterd A Mali WP Doevendans PA Bots ML et al . Identifying Coronary Artery Disease in Asymptomatic Middle-Aged Sportsmen: The Additional Value of Pulse Wave Velocity. PLoS One. (2015) 10:e0131895. doi: 10.1371/journal.pone.0131895

  • CrossRef
  • Google Scholar

• 126

  Kelly CJ Speirs A Gould GW Petrie JR Lyall H Connell JM . Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. (2002) 87:742–6. doi: 10.1210/jcem.87.2.8199

  • CrossRef
  • Google Scholar

• 127

  Wang A Su Z Liu X Yang Y Chen S Wang S et al . Brachial-ankle pulse wave velocity and metabolic syndrome in general population: the APAC study. BMC Cardiovasc Disord. (2016) 16:228. doi: 10.1186/s12872-016-0409-x

  • CrossRef
  • Google Scholar

• 128

  Mancia G Fagard R Narkiewicz K Redon J Zanchetti A Böhm M et al . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. (2013) 34(28):2159–219. doi: 10.1093/eurheartj/eht151

  • CrossRef
  • Google Scholar

• 129

  Naqvi TZ Lee MS . Carotid intima-media thickness and plaque in cardiovascular risk assessment. JACC Cardiovasc Imaging. (2014) 7:1025–38. doi: 10.1016/j.jcmg.2013.11.014

  • CrossRef
  • Google Scholar

• 130

  Enderle MD Schroeder S Ossen R Meisner C Baumbach A Haering HU et al . Comparison of peripheral endothelial dysfunction and intimal media thickness in patients with suspected coronary artery disease. Heart. (1998) 80:349–54. doi: 10.1136/hrt.80.4.349

  • CrossRef
  • Google Scholar

• 131

  Hashimoto M Eto M Akishita M Kozaki K Ako J Iijima K et al . Correlation between flow-mediated vasodilatation of the brachial artery and intima-media thickness in the carotid artery in men. Arterioscler Thromb Vasc Biol. (1999) 19:2795–800. doi: 10.1161/01.ATV.19.11.2795

  • CrossRef
  • Google Scholar

• 132

  Abd El Dayem SM Anwar GM Salama H Kamel AF Emara N . Bone mineral density, bone turnover markers, lean mass, and fat mass in Egyptian children with congenital adrenal hyperplasia. Arch Med Sci. (2010) 6:104–10. doi: 10.5114/aoms.2010.13516

  • CrossRef
  • Google Scholar

• 133

  Sartorato P Zulian E Benedini S Mariniello B Schiavi F Bilora F et al . Cardiovascular risk factors and ultrasound evaluation of intima-media thickness at common carotids, carotid bulbs, and femoral and abdominal aorta arteries in patients with classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Clin Endocrinol Metab. (2007) 92:1015–8. doi: 10.1210/jc.2006-1711

  • CrossRef
  • Google Scholar

• 134

  Akyurek N Atabek ME Eklioglu BS Alp H . Ambulatory blood pressure and subclinical cardiovascular disease in patients with congenital adrenal hyperplasia: a preliminary report. J Clin Res Pediatr Endocrinol. (2015) 7:13–8. doi: 10.4274/jcrpe.1658

  • CrossRef
  • Google Scholar

• 135

  Metwalley KA . Left ventricular dysfunction and subclinical atherosclerosis in children with classic congenital adrenal hyperplasia: a single-center study from Upper Egypt. Eur J Pediatr. (2016) 175:415. doi: 10.1007/s00431-015-2678-2

  • CrossRef
  • Google Scholar

• 136

  Rodrigues TM Barra CB Santos JL Goulart EM Ferreira AV Silva IN . Cardiovascular risk factors and increased carotid intima-media thickness in young patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Arch Endocrinol Metab. (2015) 59:541–7. doi: 10.1590/2359-3997000000119

  • CrossRef
  • Google Scholar

• 137

  Amr NH Ahmed AY Ibrahim YA . Carotid intima media thickness and other cardiovascular risk factors in children with congenital adrenal hyperplasia. J Endocrinol Invest. (2014) 37:1001–8. doi: 10.1007/s40618-014-0148-8

  • CrossRef
  • Google Scholar

• 138

  Wasniewska M Balsamo A Valenzise M Manganaro A Faggioli G Bombaci S et al . Increased large artery intima media thickness in adolescents with either classical or non-classical congenital adrenal hyperplasia. J Endocrinol Invest. (2013) 36:12–5. doi: 10.1007/BF03346751

  • CrossRef
  • Google Scholar

• 139

  Ozdemir R Korkmaz HA Kucuk M Karadeniz C Mese T Ozkan B . Assessment of early atherosclerosis and left ventricular dysfunction in children with 21-hydroxylase deficiency. Clin Endocrinol (Oxf). (2017) 86:473–9. doi: 10.1111/cen.13275

  • CrossRef
  • Google Scholar

• 140

  Kim MS Dao-Tran A Davidowitz E Tseng T Gilsanz V Ryabets-Lienhard A et al . Carotid Intima-Media Thickness Is Associated with Increased Androgens in Adolescents and Young Adults with Classical Congenital Adrenal Hyperplasia. Horm Res Paediatr. (2016) 85:242–9. doi: 10.1159/000444169

  • CrossRef
  • Google Scholar

• 141

  Ines D Ivana J Ana S Anita C Marko S Kristina S-R . The Markers of Endothelial Activation. In: HelenaL, editor. Endothelial Dysfunction. IntechOpen, Rijeka (2018). p. Ch. 17.

  • Google Scholar

• 142

  Constans J Conri C . Circulating markers of endothelial function in cardiovascular disease. Clin Chim Acta. (2006) 368:33–47. doi: 10.1016/j.cca.2005.12.030

  • CrossRef
  • Google Scholar

• 143

  Rabelink TJ de Boer HC van Zonneveld AJ . Endothelial activation and circulating markers of endothelial activation in kidney disease. Nat Rev Nephrol. (2010) 6:404–14. doi: 10.1038/nrneph.2010.65

  • CrossRef
  • Google Scholar

• 144

  Cooke JP Wilson AM . Biomarkers of peripheral arterial disease. J Am Coll Cardiol. (2010) 55:2017–23. doi: 10.1016/j.jacc.2009.08.090

  • CrossRef
  • Google Scholar

• 145

  Zhang J Defelice AF Hanig JP Colatsky T . Biomarkers of endothelial cell activation serve as potential surrogate markers for drug-induced vascular injury. Toxicol Pathol. (2010) 38:856–71. doi: 10.1177/0192623310378866

  • CrossRef
  • Google Scholar

• 146

  Qiu Y Zhang C Zhang G Tao J . Endothelial progenitor cells in cardiovascular diseases. Aging Med (Milton). (2018) 1:204–8. doi: 10.1002/agm2.12041

  • CrossRef
  • Google Scholar

• 147

  Hill JM Zalos G Halcox JP Schenke WH Waclawiw MA Quyyumi AA et al . Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med. (2003) 348:593–600. doi: 10.1056/NEJMoa022287

  • CrossRef
  • Google Scholar

• 148

  Helbing T Olivier C Bode C Moser M Diehl P . Role of microparticles in endothelial dysfunction and arterial hypertension. World J Cardiol. (2014) 6:1135–9. doi: 10.4330/wjc.v6.i11.1135

  • CrossRef
  • Google Scholar

• 149

  Kumar S Williams D Sur S Wang JY Jo H . Role of flow-sensitive microRNAs and long noncoding RNAs in vascular dysfunction and atherosclerosis. Vascul Pharmacol. (2019) 114:76–92. doi: 10.1016/j.vph.2018.10.001

  • CrossRef
  • Google Scholar

• 150

  Menghini R Casagrande V Federici M . MicroRNAs in endothelial senescence and atherosclerosis. J Cardiovasc Transl Res. (2013) 6:924–30. doi: 10.1007/s12265-013-9487-7

  • CrossRef
  • Google Scholar

• 151

  Perkins LA Anderson CJ Novelli EM . Targeting P-Selectin Adhesion Molecule in Molecular Imaging: P-Selectin Expression as a Valuable Imaging Biomarker of Inflammation in Cardiovascular Disease. J Nucl Med. (2019) 60:1691–7. doi: 10.2967/jnumed.118.225169

  • CrossRef
  • Google Scholar

• 152

  Zhang J Huang S Zhu Z Gatt A Liu J . E-selectin in vascular pathophysiology. Front Immunol. (2024) 15:1401399. doi: 10.3389/fimmu.2024.1401399

  • CrossRef
  • Google Scholar

• 153

  Galkina E Ley K . Vascular adhesion molecules in atherosclerosis. Arterioscler Thromb Vasc Biol. (2007) 27:2292–301. doi: 10.1161/ATVBAHA.107.149179

  • CrossRef
  • Google Scholar

• 154

  Horvath B Hegedus D Szapary L Marton Z Alexy T Koltai K et al . Measurement of von Willebrand factor as the marker of endothelial dysfunction in vascular diseases. Exp Clin Cardiol. (2004) 9:31–4.

  • Google Scholar

• 155

  Fuchs D Avanzas P Arroyo-Espliguero R Jenny M Consuegra-Sanchez L Kaski JC . The role of neopterin in atherogenesis and cardiovascular risk assessment. Curr Med Chem. (2009) 16:4644–53. doi: 10.2174/092986709789878247

  • CrossRef
  • Google Scholar

• 156

  B KGEEAYBES . The role of osteoprotegerin and sclerostin in bone metabolism in children with congenital adrenal hyperplasia. In: 25th European Congress of Endocrinology 13 May 2023–16 May 2023. European Society of Endocrinology, Istanbul, Turkey (2023).

  • Google Scholar

• 157

  Kurnaz E Cetinkaya S Ozalkak S Bayramoglu E Demirci G Ozturk HS et al . Serum Fetuin-A and Insulin Levels in Classic Congenital Adrenal Hyperplasia. Horm Metab Res. (2020) 52:654–9. doi: 10.1055/a-1116-2173

  • CrossRef
  • Google Scholar

• 158

  Falhammar H Filipsson Nystrom H Wedell A Thoren M . Cardiovascular risk, metabolic profile, and body composition in adult males with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. Eur J Endocrinol. (2011) 164:285–93. doi: 10.1530/EJE-10-0877

  • CrossRef
  • Google Scholar

• 159

  Metwalley KA Farghaly HS Abdelhamid A . Homocysteine Level in Children with Classic Congenital Adrenal Hyperplasia: Relationship to Carotid Intimal Wall Thickness and Left Ventricular Function. Horm Res Paediatr. (2018) 90:228–35. doi: 10.1159/000492900

  • CrossRef
  • Google Scholar

• 160

  Borges JH de Oliveira DM de Lemos-Marini SHV Geloneze B Gonçalves EM Guerra-Júnior G . Fat Distribution and Lipid Profile of Young Adults with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Enzyme Deficiency. Lipids. (2021) 56:101–10. doi: 10.1002/lipd.12280

  • CrossRef
  • Google Scholar

• 161

  Volkl TM Simm D Korner A Rascher W Kiess W Kratzsch J et al . Does an altered leptin axis play a role in obesity among children and adolescents with classical congenital adrenal hyperplasia due to 21-hydroxylase deficiency? Eur J Endocrinol. (2009) 160:239–47. doi: 10.1530/EJE-08-0770

  • CrossRef
  • Google Scholar

• 162

  Isguven P Arslanoglu I Mesutoglu N Yildiz M Erguven M . Bioelectrical impedance analysis of body fatness in childhood congenital adrenal hyperplasia and its metabolic correlates. Eur J Pediatr. (2008) 167:1263–8. doi: 10.1007/s00431-007-0665-y

  • CrossRef
  • Google Scholar

• 163

  Saygili F Oge A Yilmaz C . Hyperinsulinemia and insulin insensitivity in women with nonclassical congenital adrenal hyperplasia due to 21-hydroxylase deficiency: the relationship between serum leptin levels and chronic hyperinsulinemia. Horm Res. (2005) 63:270–4. doi: 10.1159/000086363

  • CrossRef
  • Google Scholar

• 164

  Volkl TM Simm D Korner A Kiess W Kratzsch J Dorr HG . Adiponectin levels are high in children with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency. Acta Paediatr. (2009) 98:885–91. doi: 10.1111/j.1651-2227.2009.01231.x

  • CrossRef
  • Google Scholar

• 165

  Singh U Devaraj S Vasquez-Vivar J Jialal I . C-reactive protein decreases endothelial nitric oxide synthase activity via uncoupling. J Mol Cell Cardiol. (2007) 43:780–91. doi: 10.1016/j.yjmcc.2007.08.015

  • CrossRef
  • Google Scholar

• 166

  Delai A Gomes PM Foss-Freitas MC Elias J Antonini SR Castro M et al . Hyperinsulinemic-Euglycemic Clamp Strengthens the Insulin Resistance in Nonclassical Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. (2022) 107:e1106–e16. doi: 10.1210/clinem/dgab767

  • CrossRef
  • Google Scholar

• 167

  Angelopoulou MV Kontogiorgos E Emmanouil D . Congenital adrenal hyperplasia: a case report with premature teeth exfoliation and bone resorption. Pediatrics. (2015) 135:e1524–9. doi: 10.1542/peds.2014-3577

  • CrossRef
  • Google Scholar

• 168

  Walczak M Suraj J Kus K Kij A Zakrzewska A Chlopicki S . Towards a comprehensive endothelial biomarkers profiling and endothelium-guided pharmacotherapy. Pharmacol Rep. (2015) 67:771–7. doi: 10.1016/j.pharep.2015.06.008

  • CrossRef
  • Google Scholar

• 169

  Gieseg SP Crone EM Flavall EA Amit Z . Potential to inhibit growth of atherosclerotic plaque development through modulation of macrophage neopterin/7,8-dihydroneopterin synthesis. Br J Pharmacol. (2008) 153:627–35. doi: 10.1038/sj.bjp.0707408

  • CrossRef
  • Google Scholar

• 170

  Cirillo P Pacileo M De Rosa S CalabrÒ P Gargiulo A Angri V et al . Neopterin induces pro&x2010;atherothrombotic phenotype in human coronary endothelial cells. J Thromb Haemostasis. (2006) 4:2248–55. doi: 10.1111/j.1538-7836.2006.02125.x

  • CrossRef
  • Google Scholar

• 171

  Shirai R Sato K Yamashita T Yamaguchi M Okano T Watanabe-Kominato K et al . Neopterin Counters Vascular Inflammation and Atherosclerosis. J Am Heart Assoc. (2018) 7. doi: 10.1161/JAHA.117.007359

  • CrossRef
  • Google Scholar

• 172

  Murr C Fuith LC Widner B Wirleitner B Baier-Bitterlich G Fuchs D . Increased neopterin concentrations in patients with cancer: indicator of oxidative stress? Anticancer Res. (1999) 19:1721–8.

  • Google Scholar

• 173

  Tatzber F Rabl H Koriska K Erhart U Puhl H Waeg G et al . Elevated serum neopterin levels in atherosclerosis. Atherosclerosis. (1991) 89:203–8. doi: 10.1016/0021-9150(91)90061-7

  • CrossRef
  • Google Scholar

• 174

  Weiss G Willeit J Kiechl S Fuchs D Jarosch E Oberhollenzer F et al . Increased concentrations of neopterin in carotid atherosclerosis. Atherosclerosis. (1994) 106:263–71. doi: 10.1016/0021-9150(94)90131-7

  • CrossRef
  • Google Scholar

• 175

  Liu Y Chen F Zeng Z Lei C Chen D Zhang X . Neopterin in patients with COPD, asthma, and ACO: association with endothelial and lung functions. Respir Res. (2024) 25:171. doi: 10.1186/s12931-024-02784-4

  • CrossRef
  • Google Scholar

• 176

  Zhang YY Tong XZ Xia WH Xie WL Yu BB Zhang B et al . Increased plasma neopterin levels are associated with reduced endothelial function and arterial elasticity in hypertension. J Hum Hypertens. (2016) 30:436–41. doi: 10.1038/jhh.2015.72

  • CrossRef
  • Google Scholar

• 177

  Meng LL Cao L . Serum neopterin levels and their role in the prognosis of patients with ischemic stroke: A systematic review and meta-analysis. J Clin Neurosci. (2021) 92:55–60. doi: 10.1016/j.jocn.2021.07.033

  • CrossRef
  • Google Scholar

• 178

  Simonet WS Lacey DL Dunstan CR Kelley M Chang MS Lüthy R et al . Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell. (1997) 89:309–19. doi: 10.1016/S0092-8674(00)80209-3

  • CrossRef
  • Google Scholar

• 179

  Lacey DL Timms E Tan HL Kelley MJ Dunstan CR Burgess T et al . Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell. (1998) 93:165–76. doi: 10.1016/S0092-8674(00)81569-X

  • CrossRef
  • Google Scholar

• 180

  Fuller K Wong B Fox S Choi Y Chambers TJ . TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts. J Exp Med. (1998) 188:997–1001. doi: 10.1084/jem.188.5.997

  • CrossRef
  • Google Scholar

• 181

  Emery JG McDonnell P Burke MB Deen KC Lyn S Silverman C et al . Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J Biol Chem. (1998) 273:14363–7. doi: 10.1074/jbc.273.23.14363

  • CrossRef
  • Google Scholar

• 182

  Tintut Y Demer L . Role of osteoprotegerin and its ligands and competing receptors in atherosclerotic calcification. J Invest Med. (2006) 54:395–401. doi: 10.2310/6650.2006.06019

  • CrossRef
  • Google Scholar

• 183

  Ziegler S Kudlacek S Luger A Minar E . Osteoprotegerin plasma concentrations correlate with severity of peripheral artery disease. Atherosclerosis. (2005) 182:175–80. doi: 10.1016/j.atherosclerosis.2005.01.042

  • CrossRef
  • Google Scholar

• 184

  Mogelvang R Pedersen SH Flyvbjerg A Bjerre M Iversen AZ Galatius S et al . Comparison of osteoprotegerin to traditional atherosclerotic risk factors and high-sensitivity C-reactive protein for diagnosis of atherosclerosis. Am J Cardiol. (2012) 109:515–20. doi: 10.1016/j.amjcard.2011.09.043

  • CrossRef
  • Google Scholar

• 185

  Tschiderer L Willeit J Schett G Kiechl S Willeit P . Osteoprotegerin concentration and risk of cardiovascular outcomes in nine general population studies: Literature-based meta-analysis involving 26,442 participants. PLoS One. (2017) 12:e0183910. doi: 10.1371/journal.pone.0183910

  • CrossRef
  • Google Scholar

• 186

  Zhao H Cao Y Chen H Xu W Sun X Pan X . The association between OPG rs3102735 gene polymorphism, microembolic signal and stroke severity in acute ischemic stroke patients. Gene. (2017) 613:25–9. doi: 10.1016/j.gene.2017.02.029

  • CrossRef
  • Google Scholar

• 187

  Abedin M Tintut Y Demer LL . Vascular calcification: mechanisms and clinical ramifications. Arterioscler Thromb Vasc Biol. (2004) 24:1161–70. doi: 10.1161/01.ATV.0000133194.94939.42

  • CrossRef
  • Google Scholar

• 188

  Persy V D’Haese P . Vascular calcification and bone disease: the calcification paradox. Trends Mol Med. (2009) 15:405–16. doi: 10.1016/j.molmed.2009.07.001

  • CrossRef
  • Google Scholar

• 189

  Rochette L Meloux A Rigal E Zeller M Cottin Y Vergely C . The Role of Osteoprotegerin and Its Ligands in Vascular Function. Int J Mol Sci. (2019) 20. doi: 10.3390/ijms20030705

  • CrossRef
  • Google Scholar

• 190

  Dutka M Bobiński R Wojakowski W Francuz T Pająk C Zimmer K . Osteoprotegerin and RANKL-RANK-OPG-TRAIL signalling axis in heart failure and other cardiovascular diseases. Heart Fail Rev. (2022) 27:1395–411. doi: 10.1007/s10741-021-10153-2

  • CrossRef
  • Google Scholar

• 191

  Zauli G Corallini F Bossi F Fischetti F Durigutto P Celeghini C et al . Osteoprotegerin increases leukocyte adhesion to endothelial cells both in vitro and in vivo. Blood. (2007) 110:536–43. doi: 10.1182/blood-2007-01-068395

  • CrossRef
  • Google Scholar

• 192

  Wang HH Xiang GD . Changes of plasma concentration of osteoprotegerin and its association with endothelial dysfunction before and after hypouricemic therapy in patients with hyperuricemia. Mod Rheumatol. (2015) 25:123–7. doi: 10.3109/14397595.2014.926852

  • CrossRef
  • Google Scholar

• 193

  Shin JY Shin YG Chung CH . Elevated serum osteoprotegerin levels are associated with vascular endothelial dysfunction in type 2 diabetes. Diabetes Care. (2006) 29:1664–6. doi: 10.2337/dc06-0631

  • CrossRef
  • Google Scholar

• 194

  D’Abramo A Zingaropoli MA Oliva A D’Agostino C Al Moghazi S De Luca G et al . Immune activation, immunosenescence, and osteoprotegerin as markers of endothelial dysfunction in subclinical HIV-associated atherosclerosis. Mediators Inflamm. (2014) 2014:192594. doi: 10.1155/2014/192594

  • CrossRef
  • Google Scholar

• 195

  Gunes M Temizkan S Apaydin T Ilgin C Haklar G Gogas Yavuz D . Serum osteoprotegerin levels, endothelial function and carotid intima-media thickness in type 2 diabetic patients. J Diabetes Complications. (2021) 35:108073. doi: 10.1016/j.jdiacomp.2021.108073

  • CrossRef
  • Google Scholar

• 196

  Abali R Tasdemir N Alpsoy S Tasdemir UG Guzel S Yuksel MA et al . No relationship between osteoprotegerin concentrations and endothelial dysfunction in non-obese women with and without polycystic ovary syndrome. Arch Gynecol Obstet. (2015) 291:1075–80. doi: 10.1007/s00404-014-3499-7

  • CrossRef
  • Google Scholar

• 197

  Trepanowski JF Mey J Varady KA . Fetuin-A: a novel link between obesity and related complications. Int J Obesity. (2015) 39:734–41. doi: 10.1038/ijo.2014.203

  • CrossRef
  • Google Scholar

• 198

  Goustin A-S Abou-Samra AB . The “thrifty” gene encoding Ahsg/Fetuin-A meets the insulin receptor: Insights into the mechanism of insulin resistance. Cell Signalling. (2011) 23:980–90. doi: 10.1016/j.cellsig.2010.11.003

  • CrossRef
  • Google Scholar

• 199

  Stefan N Hennige AM Staiger H Machann J Schick F Krober SM et al . Alpha2-Heremans-Schmid glycoprotein/fetuin-A is associated with insulin resistance and fat accumulation in the liver in humans. Diabetes Care. (2006) 29:853–7. doi: 10.2337/diacare.29.04.06.dc05-1938

  • CrossRef
  • Google Scholar

• 200

  Ou HY Yang YC Wu HT Wu JS Lu FH Chang CJ . Increased fetuin-A concentrations in impaired glucose tolerance with or without nonalcoholic fatty liver disease, but not impaired fasting glucose. J Clin Endocrinol Metab. (2012) 97:4717–23. doi: 10.1210/jc.2012-2414

  • CrossRef
  • Google Scholar

• 201

  Ix JH Shlipak MG Brandenburg VM Ali S Ketteler M Whooley MA . Association between human fetuin-A and the metabolic syndrome: data from the Heart and Soul Study. Circulation. (2006) 113:1760–7. doi: 10.1161/CIRCULATIONAHA.105.588723

  • CrossRef
  • Google Scholar

• 202

  Hennige AM Staiger H Wicke C Machicao F Fritsche A Haring HU et al . Fetuin-A induces cytokine expression and suppresses adiponectin production. PLoS One. (2008) 3:e1765. doi: 10.1371/journal.pone.0001765

  • CrossRef
  • Google Scholar

• 203

  Schafer C Heiss A Schwarz A Westenfeld R Ketteler M Floege J et al . The serum protein alpha 2-Heremans-Schmid glycoprotein/fetuin-A is a systemically acting inhibitor of ectopic calcification. J Clin Invest. (2003) 112:357–66. doi: 10.1172/JCI17202

  • CrossRef
  • Google Scholar

• 204

  Jahnen-Dechent W Heiss A Schäfer C Ketteler M . Fetuin-A regulation of calcified matrix metabolism. Circ Res. (2011) 108:1494–509. doi: 10.1161/CIRCRESAHA.110.234260

  • CrossRef
  • Google Scholar

• 205

  Hamano T Matsui I Mikami S Tomida K Fujii N Imai E et al . Fetuin-mineral complex reflects extraosseous calcification stress in CKD. J Am Soc Nephrol. (2010) 21:1998–2007. doi: 10.1681/ASN.2009090944

  • CrossRef
  • Google Scholar

• 206

  Ismail NA Ragab S El Dayem SM Elbaky AA Salah N Hamed M et al . Fetuin-A levels in obesity: differences in relation to metabolic syndrome and correlation with clinical and laboratory variables. Arch Med Sci. (2012) 8:826–33. doi: 10.5114/aoms.2012.31616

  • CrossRef
  • Google Scholar

• 207

  Ix JH Wassel CL Kanaya AM Vittinghoff E Johnson KC Koster A et al . Fetuin-A and incident diabetes mellitus in older persons. JAMA. (2008) 300:182–8. doi: 10.1001/jama.300.2.182

  • CrossRef
  • Google Scholar

• 208

  Liu S Hu W He Y Li L Liu H Gao L et al . Serum Fetuin-A levels are increased and associated with insulin resistance in women with polycystic ovary syndrome. BMC Endocr Disord. (2020) 20:67. doi: 10.1186/s12902-020-0538-1

  • CrossRef
  • Google Scholar

• 209

  Enli Y Fenkci SM Fenkci V Oztekin O . Serum Fetuin-A levels, insulin resistance and oxidative stress in women with polycystic ovary syndrome. Gynecological Endocrinology. (2013) 29:1036–9. doi: 10.3109/09513590.2013.829442

  • CrossRef
  • Google Scholar

• 210

  Djuric D Jakovljevic V Zivkovic V Srejovic I . Homocysteine and homocysteine-related compounds: an overview of the roles in the pathology of the cardiovascular and nervous systems. Can J Physiol Pharmacol. (2018) 96:991–1003. doi: 10.1139/cjpp-2018-0112

  • CrossRef
  • Google Scholar

• 211

  Paganelli F Mottola G Fromonot J Marlinge M Deharo P Guieu R et al . Hyperhomocysteinemia and Cardiovascular Disease: Is the Adenosinergic System the Missing Link? Int J Mol Sci. (2021) 22. doi: 10.3390/ijms22041690

  • CrossRef
  • Google Scholar

• 212

  Stehouwer CD Weijenberg MP van den Berg M Jakobs C Feskens EJ Kromhout D . Serum homocysteine and risk of coronary heart disease and cerebrovascular disease in elderly men: a 10-year follow-up. Arterioscler Thromb Vasc Biol. (1998) 18:1895–901. doi: 10.1161/01.ATV.18.12.1895

  • CrossRef
  • Google Scholar

• 213

  Catena C Colussi G Nait F Capobianco F Sechi LA . Elevated Homocysteine Levels Are Associated With the Metabolic Syndrome and Cardiovascular Events in Hypertensive Patients. Am J Hypertens. (2015) 28:943–50. doi: 10.1093/ajh/hpu248

  • CrossRef
  • Google Scholar

• 214

  Baszczuk A Kopczynski Z . Hyperhomocysteinemia in patients with cardiovascular disease. Postepy Hig Med Dosw (Online). (2014) 68:579–89. doi: 10.5604/17322693.1102340

  • CrossRef
  • Google Scholar

• 215

  Shenoy V Mehendale V Prabhu K Shetty R Rao P . Correlation of serum homocysteine levels with the severity of coronary artery disease. Indian J Clin Biochem. (2014) 29:339–44. doi: 10.1007/s12291-013-0373-5

  • CrossRef
  • Google Scholar

• 216

  Jin N Huang L Hong J Zhao X Chen Y Hu J et al . Elevated homocysteine levels in patients with heart failure: A systematic review and meta-analysis. Med (Baltimore). (2021) 100:e26875. doi: 10.1097/MD.0000000000026875

  • CrossRef
  • Google Scholar

• 217

  Sharma M Tiwari M Tiwari RK . Hyperhomocysteinemia: Impact on Neurodegenerative Diseases. Basic Clin Pharmacol Toxicol. (2015) 117:287–96. doi: 10.1111/bcpt.2015.117.issue-5

  • CrossRef
  • Google Scholar

• 218

  Skovierova H Vidomanova E Mahmood S Sopkova J Drgova A Cervenova T et al . The Molecular and Cellular Effect of Homocysteine Metabolism Imbalance on Human Health. Int J Mol Sci. (2016) 17. doi: 10.3390/ijms17101733

  • CrossRef
  • Google Scholar

• 219

  Pushpakumar S Kundu S Sen U . Endothelial dysfunction: the link between homocysteine and hydrogen sulfide. Curr Med Chem. (2014) 21:3662–72. doi: 10.2174/0929867321666140706142335

  • CrossRef
  • Google Scholar

• 220

  Yuan D Chu J Lin H Zhu G Qian J Yu Y et al . Mechanism of homocysteine-mediated endothelial injury and its consequences for atherosclerosis. Front Cardiovasc Med. (2022) 9:1109445. doi: 10.3389/fcvm.2022.1109445

  • CrossRef
  • Google Scholar

• 221

  Austin RC Lentz SR Werstuck GH . Role of hyperhomocysteinemia in endothelial dysfunction and atherothrombotic disease. Cell Death Differentiation. (2004) 11:S56–64. doi: 10.1038/sj.cdd.4401451

  • CrossRef
  • Google Scholar

• 222

  Krysiak R Kowalcze K Marek B Okopień B . Cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia. Acta Cardiol. (2020) 75:705–10. doi: 10.1080/00015385.2019.1666964

  • CrossRef
  • Google Scholar

• 223

  Dierkes J Jeckel A Ambrosch A Westphal S Luley C Boeing H . Factors explaining the difference of total homocysteine between men and women in the European Investigation Into Cancer and Nutrition Potsdam study. Metabolism. (2001) 50:640–5. doi: 10.1053/meta.2001.23286

  • CrossRef
  • Google Scholar

• 224

  Maleedhu P MV SBS S Kodumuri PK Devi DV . Status of Homocysteine in Polycystic Ovary Syndrome (PCOS). J Clin Diagn Res. (2014) 8:31–3. doi: 10.7860/JCDR/2014/7070.3999

  • CrossRef
  • Google Scholar

• 225

  Loverro G Lorusso F Mei L Depalo R Cormio G Selvaggi L . The plasma homocysteine levels are increased in polycystic ovary syndrome. Gynecol Obstet Invest. (2002) 53:157–62. doi: 10.1159/000058367

  • CrossRef
  • Google Scholar

• 226

  Badawy A State O El Gawad SSA El Aziz OA . Plasma homocysteine and polycystic ovary syndrome: the missed link. Eur J Obstet Gynecol Reprod Biol. (2007) 131:68–72. doi: 10.1016/j.ejogrb.2006.10.015

  • CrossRef
  • Google Scholar

• 227

  Karatela RA Sainani GS . Plasma homocysteine in obese, overweight and normal weight hypertensives and normotensives. Indian Heart J. (2009) 61:156–9.

  • Google Scholar

• 228

  Vayá A Rivera L Hernández-Mijares A de la Fuente M Solá E Romagnoli M et al . Homocysteine levels in morbidly obese patients. Its association with waist circumference and insulin resistance. Clin Hemorheology Microcirculation. (2012) 52:49–56. doi: 10.3233/CH-2012-1544

  • CrossRef
  • Google Scholar

• 229

  Denver RJ Bonett RM Boorse GC . Evolution of leptin structure and function. Neuroendocrinology. (2011) 94:21–38. doi: 10.1159/000328435

  • CrossRef
  • Google Scholar

• 230

  Chen M-C Wang J-H Lee C-J Hsu B-G . Association between hyperleptinemia and cardiovascular outcomes in patients with coronary artery disease. Ther Clin Risk Manage. (2018) 14:1855–62. doi: 10.2147/TCRM.S172231

  • CrossRef
  • Google Scholar

• 231

  Ren J . Leptin and hyperleptinemia-from friend to foe for cardiovascular function. J Endocrinology. (2004) 181:1–10. doi: 10.1677/joe.0.1810001

  • CrossRef
  • Google Scholar

• 232

  Reilly MP Iqbal N Schutta M Wolfe ML Scally M Localio AR et al . Plasma leptin levels are associated with coronary atherosclerosis in type 2 diabetes. J Clin Endocrinol Metab. (2004) 89:3872–8. doi: 10.1210/jc.2003-031676

  • CrossRef
  • Google Scholar

• 233

  Montazerifar F Bolouri A Paghalea RS Mahani MK Karajibani M . Obesity, Serum Resistin and Leptin Levels Linked to Coronary Artery Disease. Arq Bras Cardiol. (2016) 107:348–53. doi: 10.5935/abc.20160134

  • CrossRef
  • Google Scholar

• 234

  Yang H Guo W Li J Cao S Zhang J Pan J et al . Leptin concentration and risk of coronary heart disease and stroke: A systematic review and meta-analysis. PLoS One. (2017) 12:e0166360. doi: 10.1371/journal.pone.0166360

  • CrossRef
  • Google Scholar

• 235

  Nguyen TMD . Adiponectin: Role in Physiology and Pathophysiology. Int J Prev Med. (2020) 11:136. doi: 10.4103/ijpvm.IJPVM_193_20

  • CrossRef
  • Google Scholar

• 236

  Yoda-Murakami M Taniguchi M Takahashi K Kawamata S Saito K Choi-Miura NH et al . Change in expression of GBP28/adiponectin in carbon tetrachloride-administrated mouse liver. Biochem Biophys Res Commun. (2001) 285:372–7. doi: 10.1006/bbrc.2001.5134

  • CrossRef
  • Google Scholar

• 237

  Delaigle AM Jonas JC Bauche IB Cornu O Brichard SM . Induction of adiponectin in skeletal muscle by inflammatory cytokines: in vivo and in vitro studies. Endocrinology. (2004) 145:5589–97. doi: 10.1210/en.2004-0503

  • CrossRef
  • Google Scholar

• 238

  Patel JV Abraheem A Dotsenko O Creamer J Gunning M Hughes EA et al . Circulating serum adiponectin levels in patients with coronary artery disease: relationship to atherosclerotic burden and cardiac function. J Intern Med. (2008) 264:593–8. doi: 10.1111/j.1365-2796.2008.02007.x

  • CrossRef
  • Google Scholar

• 239

  Yamauchi T Kamon J Ito Y Tsuchida A Yokomizo T Kita S et al . Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. (2003) 423:762–9. doi: 10.1038/nature01705

  • CrossRef
  • Google Scholar

• 240

  Tkachuk VA Bochkov VN Philippova MP Stambolsky DV Kuzmenko ES Sidorova MV et al . Identification of an atypical lipoprotein-binding protein from human aortic smooth muscle as T-cadherin. FEBS Lett. (1998) 421:208–12. doi: 10.1016/S0014-5793(97)01562-7

  • CrossRef
  • Google Scholar

• 241

  Wyder L Vitaliti A Schneider H Hebbard LW Moritz DR Wittmer M et al . Increased expression of H/T-cadherin in tumor-penetrating blood vessels. Cancer Res. (2000) 60:4682–8.

  • Google Scholar

• 242

  Ivanov D Philippova M Antropova J Gubaeva F Iljinskaya O Tararak E et al . Expression of cell adhesion molecule T-cadherin in the human vasculature. Histochem Cell Biol. (2001) 115:231–42. doi: 10.1007/s004180100252

  • CrossRef
  • Google Scholar

• 243

  Sattar N Wannamethee G Sarwar N Tchernova J Cherry L Wallace AM et al . Adiponectin and coronary heart disease: a prospective study and meta-analysis. Circulation. (2006) 114:623–9. doi: 10.1161/CIRCULATIONAHA.106.618918

  • CrossRef
  • Google Scholar

• 244

  Iwashima Y Katsuya T Ishikawa K Ouchi N Ohishi M Sugimoto K et al . Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. (2004) 43:1318–23. doi: 10.1161/01.HYP.0000129281.03801.4b

  • CrossRef
  • Google Scholar

• 245

  Lam KS Xu A . Adiponectin: protection of the endothelium. Curr Diabetes Rep. (2005) 5:254–9. doi: 10.1007/s11892-005-0019-y

  • CrossRef
  • Google Scholar

• 246

  Smekal A Vaclavik J . Adipokines and cardiovascular disease: A comprehensive review. BioMed Pap Med Fac Univ Palacky Olomouc Czech Repub. (2017) 161:31–40. doi: 10.5507/bp.2017.002

  • CrossRef
  • Google Scholar

• 247

  Nakamura K Fuster JJ Walsh K . Adipokines: a link between obesity and cardiovascular disease. J Cardiol. (2014) 63:250–9. doi: 10.1016/j.jjcc.2013.11.006

  • CrossRef
  • Google Scholar

• 248

  Shibata R Izumiya Y Sato K Papanicolaou K Kihara S Colucci WS et al . Adiponectin protects against the development of systolic dysfunction following myocardial infarction. J Mol Cell Cardiol. (2007) 42:1065–74. doi: 10.1016/j.yjmcc.2007.03.808

  • CrossRef
  • Google Scholar

• 249

  Wang Y Ma XL Lau WB . Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Receptor Modification. Trends Endocrinol Metab. (2017) 28:519–30. doi: 10.1016/j.tem.2017.03.004

  • CrossRef
  • Google Scholar

• 250

  Weyer C Funahashi T Tanaka S Hotta K Matsuzawa Y Pratley RE et al . Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. (2001) 86:1930–5. doi: 10.1210/jcem.86.5.7463

  • CrossRef
  • Google Scholar

• 251

  Degawa-Yamauchi M Moss KA Bovenkerk JE Shankar SS Morrison CL Lelliott CJ et al . Regulation of adiponectin expression in human adipocytes: effects of adiposity, glucocorticoids, and tumor necrosis factor alpha. Obes Res. (2005) 13:662–9. doi: 10.1038/oby.2005.74

  • CrossRef
  • Google Scholar

• 252

  Bottner A Kratzsch J Muller G Kapellen TM Bluher S Keller E et al . Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab. (2004) 89:4053–61. doi: 10.1210/jc.2004-0303

  • CrossRef
  • Google Scholar

• 253

  Ginsburg D Zeheb R Yang AY Rafferty UM Andreasen PA Nielsen L et al . cDNA cloning of human plasminogen activator-inhibitor from endothelial cells. J Clin Invest. (1986) 78:1673–80. doi: 10.1172/JCI112761

  • CrossRef
  • Google Scholar

• 254

  Vaughan DE . PAI-1 and atherothrombosis. J Thromb Haemost. (2005) 3:1879–83. doi: 10.1111/j.1538-7836.2005.01420.x

  • CrossRef
  • Google Scholar

• 255

  Yarmolinsky J Bordin Barbieri N Weinmann T Ziegelmann PK Duncan BB Ines Schmidt M . Plasminogen activator inhibitor-1 and type 2 diabetes: a systematic review and meta-analysis of observational studies. Sci Rep. (2016) 6:17714. doi: 10.1038/srep17714

  • CrossRef
  • Google Scholar

• 256

  Festa A D’Agostino R Jr. Tracy RP Haffner SM . Insulin Resistance Atherosclerosis S. Elevated levels of acute-phase proteins and plasminogen activator inhibitor-1 predict the development of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes. (2002) 51:1131–7. doi: 10.2337/diabetes.51.4.1131

  • CrossRef
  • Google Scholar

• 257

  Alessi MC Poggi M Juhan-Vague I . Plasminogen activator inhibitor-1, adipose tissue and insulin resistance. Curr Opin Lipidol. (2007) 18:240–5. doi: 10.1097/MOL.0b013e32814e6d29

  • CrossRef
  • Google Scholar

• 258

  Orio F Jr. Palomba S Cascella T Tauchmanova L Nardo LG Di Biase S et al . Is plasminogen activator inhibitor-1 a cardiovascular risk factor in young women with polycystic ovary syndrome? Reprod BioMed Online. (2004) 9:505–10. doi: 10.1016/s1472-6483(10)61634-3

  • CrossRef
  • Google Scholar

• 259

  Tarkun I Canturk Z Arslan BC Turemen E Tarkun P . The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J. (2004) 51:467–72. doi: 10.1507/endocrj.51.467

  • CrossRef
  • Google Scholar

• 260

  Iwasaki H Okamoto R Kato S Konishi K Mizutani H Yamada N et al . High glucose induces plasminogen activator inhibitor-1 expression through Rho/Rho-kinase-mediated NF-kappaB activation in bovine aortic endothelial cells. Atherosclerosis. (2008) 196:22–8. doi: 10.1016/j.atherosclerosis.2006.12.025

  • CrossRef
  • Google Scholar

• 261

  Schneider DJ Sobel BE . Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis. (1996) 7:813–7. doi: 10.1097/00019501-199611000-00004

  • CrossRef
  • Google Scholar

• 262

  Nordt TK Schneider DJ Sobel BE . Augmentation of the synthesis of plasminogen activator inhibitor type-1 by precursors of insulin. A potential Risk factor Vasc disease. Circulation. (1994) 89:321–30. doi: 10.1161/01.CIR.89.1.321

  • CrossRef
  • Google Scholar

• 263

  Chen Y Billadello JJ Schneider DJ . Identification and localization of a fatty acid response region in the human plasminogen activator inhibitor-1 gene. Arterioscler Thromb Vasc Biol. (2000) 20:2696–701. doi: 10.1161/01.ATV.20.12.2696

  • CrossRef
  • Google Scholar

• 264

  Fattal PG Schneider DJ Sobel BE Billadello JJ . Post-transcriptional regulation of expression of plasminogen activator inhibitor type 1 mRNA by insulin and insulin-like growth factor 1. J Biol Chem. (1992) 267:12412–5. doi: 10.1016/S0021-9258(18)42289-2

  • CrossRef
  • Google Scholar

• 265

  Verma S Devaraj S Jialal I . Is C-reactive protein an innocent bystander or proatherogenic culprit? C-reactive protein promotes atherothrombosis. Circulation. (2006) 113:2135–50.

  • Google Scholar

• 266

  Ridker PM Koenig W Kastelein JJ Mach F Luscher TF . Has the time finally come to measure hsCRP universally in primary and secondary cardiovascular prevention? Eur Heart J. (2018) 39:4109–11. doi: 10.1093/eurheartj/ehy723

  • CrossRef
  • Google Scholar

• 267

  Emerging Risk Factors C Kaptoge S Di Angelantonio E Pennells L Wood AM White IR et al . C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med. (2012) 367:1310–20. doi: 10.1056/NEJMoa1107477

  • CrossRef
  • Google Scholar

• 268

  Grebenciucova E VanHaerents S . Interleukin 6: at the interface of human health and disease. Front Immunol. (2023) 14:1255533. doi: 10.3389/fimmu.2023.1255533

  • CrossRef
  • Google Scholar

• 269

  Kang S Kishimoto T . Interplay between interleukin-6 signaling and the vascular endothelium in cytokine storms. Exp Mol Med. (2021) 53:1116–23. doi: 10.1038/s12276-021-00649-0

  • CrossRef
  • Google Scholar

• 270

  Didion SP . Cellular and Oxidative Mechanisms Associated with Interleukin-6 Signaling in the Vasculature. Int J Mol Sci. (2017) 18. doi: 10.3390/ijms18122563

  • CrossRef
  • Google Scholar

• 271

  Tanaka T Narazaki M Kishimoto T . IL-6 in inflammation, immunity, and disease. Cold Spring Harb Perspect Biol. (2014) 6:a016295. doi: 10.1101/cshperspect.a016295

  • CrossRef
  • Google Scholar

• 272

  Heinrich PC Castell JV Andus T . Interleukin-6 and the acute phase response. Biochem J. (1990) 265:621–36. doi: 10.1042/bj2650621

  • CrossRef
  • Google Scholar

• 273

  Ali MI Chen X Didion SP . Heterozygous eNOS deficiency is associated with oxidative stress and endothelial dysfunction in diet-induced obesity. Physiol Rep. (2015) 3. doi: 10.14814/phy2.12630

  • CrossRef
  • Google Scholar

• 274

  Wassmann S Stumpf M Strehlow K Schmid A Schieffer B Bohm M et al . Interleukin-6 induces oxidative stress and endothelial dysfunction by overexpression of the angiotensin II type 1 receptor. Circ Res. (2004) 94:534–41. doi: 10.1161/01.RES.0000115557.25127.8D

  • CrossRef
  • Google Scholar

• 275

  Han Y Runge MS Brasier AR . Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res. (1999) 84:695–703. doi: 10.1161/01.RES.84.6.695

  • CrossRef
  • Google Scholar

• 276

  Knopp T Jung R Wild J Bochenek ML Efentakis P Lehmann A et al . Myeloid cell-derived interleukin-6 induces vascular dysfunction and vascular and systemic inflammation. Eur Heart J Open. (2024) 4:oeae046. doi: 10.1093/ehjopen/oeae046

  • CrossRef
  • Google Scholar

• 277

  Katkenov N Mukhatayev Z Kozhakhmetov S Sailybayeva A Bekbossynova M Kushugulova A . Systematic Review on the Role of IL-6 and IL-1beta in Cardiovascular Diseases. J Cardiovasc Dev Dis. (2024) 11. doi: 10.3390/jcdd11070206

  • CrossRef
  • Google Scholar

• 278

  Feng Y Ye D Wang Z Pan H Lu X Wang M et al . The Role of Interleukin-6 Family Members in Cardiovascular Diseases. Front Cardiovasc Med. (2022) 9:818890. doi: 10.3389/fcvm.2022.818890

  • CrossRef
  • Google Scholar

• 279

  Blann AD Woywodt A Bertolini F Bull TM Buyon JP Clancy RM et al . Circulating endothelial cells. Biomarker of vascular disease. Thromb Haemost. (2005) 93:228–35. doi: 10.1160/TH04-09-0578

  • CrossRef
  • Google Scholar

• 280

  Smadja DM Mauge L Sanchez O Silvestre JS Guerin C Godier A et al . Distinct patterns of circulating endothelial cells in pulmonary hypertension. Eur Respir J. (2010) 36:1284–93. doi: 10.1183/09031936.00130809

  • CrossRef
  • Google Scholar

• 281

  Calderón-Colmenero J Massó F González-Pacheco H Sandoval J Guerrero C Cervantes-Salazar J et al . Pulmonary arterial hypertension in children with congenital heart disease: a deeper look into the role of endothelial progenitor cells and circulating endothelial cells to assess disease severity. Front Pediatr. (2023) 11:1200395. doi: 10.3389/fped.2023.1200395

  • CrossRef
  • Google Scholar

• 282

  Sabulski A Aunins B Abdullah S Luebbering N Davies SM . Circulating Endothelial Cells As a Marker of Vascular Injury in Pediatric Patients. Biol Blood Marrow Transplant. (2020) 26:S144–S5. doi: 10.1016/j.bbmt.2019.12.675

  • CrossRef
  • Google Scholar

• 283

  Mutin M Canavy I Blann A Bory M Sampol J Dignat-George F . Direct evidence of endothelial injury in acute myocardial infarction and unstable angina by demonstration of circulating endothelial cells. Blood. (1999) 93:2951–8. doi: 10.1182/blood.V93.9.2951.409k02_2951_2958

  • CrossRef
  • Google Scholar

• 284

  Martínez-Sales V Sánchez-Lázaro I Vila V Almenar L Contreras T Reganon E . Circulating endothelial cells in patients with heart failure and left ventricular dysfunction. Dis Markers. (2011) 31:75–82. doi: 10.1155/2011/757840

  • CrossRef
  • Google Scholar

• 285

  Alessio AM Beltrame MP Nascimento MC Vicente CP de Godoy JA Silva JC et al . Circulating progenitor and mature endothelial cells in deep vein thrombosis. Int J Med Sci. (2013) 10:1746–54. doi: 10.7150/ijms.6887

  • CrossRef
  • Google Scholar

• 286

  Rahbari NN Schölch S Bork U Kahlert C Schneider M Rahbari M et al . Prognostic value of circulating endothelial cells in metastatic colorectal cancer. Oncotarget. (2017) 8:37491–501. doi: 10.18632/oncotarget.16397

  • CrossRef
  • Google Scholar

• 287

  Goon PK Lip GY Stonelake PS Blann AD . Circulating endothelial cells and circulating progenitor cells in breast cancer: relationship to endothelial damage/dysfunction/apoptosis, clinicopathologic factors, and the Nottingham Prognostic Index. Neoplasia. (2009) 11:771–9. doi: 10.1593/neo.09490

  • CrossRef
  • Google Scholar

• 288

  Najjar F Alammar M Al-Massarani G Almalla N Japawe A Ikhtiar A . Circulating endothelial cells and microparticles as diagnostic and prognostic biomarkers in small-cell lung cancer. Lung Cancer. (2018) 124:23–30. doi: 10.1016/j.lungcan.2018.06.033

  • CrossRef
  • Google Scholar

• 289

  Zhang H Vakil V Braunstein M Smith EL Maroney J Chen L et al . Circulating endothelial progenitor cells in multiple myeloma: implications and significance. Blood. (2005) 105:3286–94. doi: 10.1182/blood-2004-06-2101

  • CrossRef
  • Google Scholar

• 290

  Szmigielska-Kaplon A Krawczynska A Czemerska M Pluta A Cebula-Obrzut B Grzybowska-Izydorczyk O et al . The kinetics and apoptotic profile of circulating endothelial cells in autologous hematopoietic stem cell transplantation in patients with lymphoproliferative disorders. Ann Hematol. (2013) 92:1255–62. doi: 10.1007/s00277-013-1759-4

  • CrossRef
  • Google Scholar

• 291

  Attia FM Maaty A Kalil FA . Circulating endothelial cells as a marker of vascular dysfunction in patients with systemic lupus erythematosus by real-time polymerase chain reaction. Arch Pathol Lab Med. (2011) 135:1482–5. doi: 10.5858/arpa.2010-0731-OA

  • CrossRef
  • Google Scholar

• 292

  Clancy R Marder G Martin V Belmont HM Abramson SB Buyon J . Circulating activated endothelial cells in systemic lupus erythematosus: further evidence for diffuse vasculopathy. Arthritis Rheumatol. (2001) 44:1203–8. doi: 10.1002/1529-0131(200105)44:5<1203::AID-ANR204>3.0.CO;2-C

  • CrossRef
  • Google Scholar

• 293

  Woywodt A Streiber F de Groot K Regelsberger H Haller H Haubitz M . Circulating endothelial cells as markers for ANCA-associated small-vessel vasculitis. Lancet. (2003) 361:206–10. doi: 10.1016/S0140-6736(03)12269-6

  • CrossRef
  • Google Scholar

• 294

  Kim SK Massett MP . Genetic Regulation of Endothelial Vasomotor Function. Front Physiol. (2016) 7:571. doi: 10.3389/fphys.2016.00571

  • CrossRef
  • Google Scholar

• 295

  Xu S Chuang CY Hawkins CL Hagglund P Davies MJ . Quantitative analysis of the proteome and protein oxidative modifications in primary human coronary artery endothelial cells and associated extracellular matrix. Redox Biol. (2025) 81:103524. doi: 10.1016/j.redox.2025.103524

  • CrossRef
  • Google Scholar

• 296

  Figuer A Santos FM Ciordia S Valera G Martin-Jouve B Hernandez-Fonseca JP et al . Proteomic analysis of endothelial cells and extracellular vesicles in response to indoxyl sulfate: Mechanisms of endothelial dysfunction in chronic kidney disease. Life Sci. (2024) 351:122810. doi: 10.1016/j.lfs.2024.122810

  • CrossRef
  • Google Scholar

• 297

  Alwahsh M Alejel R Hasan A Abuzaid H Al-Qirim T . The Application of Metabolomics in Hyperlipidemia: Insights into Biomarker Discovery and Treatment Efficacy Assessment. Metabolites. (2024) 14. doi: 10.3390/metabo14080438

  • CrossRef
  • Google Scholar

• 298

  Tschaidse L Reisch N Arlt W Brac de la Perriere A Linden Hirschberg A Juul A et al . Modified-release hydrocortisone is associated with lower plasma renin activity in patients with salt-wasting congenital adrenal hyperplasia. Eur J Endocrinol. (2023) 188:109–17. doi: 10.1093/ejendo/lvac006

  • CrossRef
  • Google Scholar

• 299

  Merke DP Mallappa A Arlt W Brac de la Perriere A Lindén Hirschberg A Juul A et al . Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. (2021) 106:e2063–e77. doi: 10.1210/clinem/dgab051

  • CrossRef
  • Google Scholar

• 300

  Mallappa A Sinaii N Kumar P Whitaker MJ Daley LA Digweed D et al . A phase 2 study of Chronocort, a modified-release formulation of hydrocortisone, in the treatment of adults with classic congenital adrenal hyperplasia. J Clin Endocrinol Metab. (2015) 100:1137–45. doi: 10.1210/jc.2014-3809

  • CrossRef
  • Google Scholar

• 301

  Arshad MF Debono M . Current and future treatment options for adrenal insufficiency. Curr Opin Endocrinol Diabetes Obes. (2021) 28:303–11. doi: 10.1097/MED.0000000000000637

  • CrossRef
  • Google Scholar

• 302

  Mongioì LM Condorelli RA Barbagallo F La Vignera S Calogero AE . Dual-release hydrocortisone for treatment of adrenal insufficiency: a systematic review. Endocrine. (2020) 67:507–15. doi: 10.1007/s12020-020-02187-7

  • CrossRef
  • Google Scholar

• 303

  Mortensen ML Ornstrup MJ Gravholt CH . Patients with Hypocortisolism Treated with Continuous Subcutaneous Hydrocortisone Infusion (CSHI): An Option for Poorly Controlled Patients. Int J Endocrinol. (2023) 2023:5315059. doi: 10.1155/2023/5315059

  • CrossRef
  • Google Scholar

• 304

  Auchus RJ Sarafoglou K Fechner PY Vogiatzi MG Imel EA Davis SM et al . Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. (2022) 107:801–12. doi: 10.1210/clinem/dgab749

  • CrossRef
  • Google Scholar

• 305

  Newfield RS Sarafoglou K Fechner PY Nokoff NJ Auchus RJ Vogiatzi MG et al . Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab. (2023) 108:2871–8. doi: 10.1210/clinem/dgad270

  • CrossRef
  • Google Scholar

• 306

  Sarafoglou K Barnes CN Huang M Imel EA Madu IJ Merke DP et al . Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies. J Clin Endocrinol Metab. (2021) 106:e4666–e79. doi: 10.1210/clinem/dgab438

  • CrossRef
  • Google Scholar

• 307

  Maher JY Gomez-Lobo V Merke DP . The management of congenital adrenal hyperplasia during preconception, pregnancy, and postpartum. Rev Endocr Metab Disord. (2023) 24:71–83. doi: 10.1007/s11154-022-09770-5

  • CrossRef
  • Google Scholar

• 308

  Curtis KM Tepper NK Jatlaoui TC Berry-Bibee E Horton LG Zapata LB et al . U.S. Medical Eligibility Criteria for Contraceptive Use, 2016. MMWR Recomm Rep. (2016) 65:1–103. doi: 10.15585/mmwr.rr6503a1

  • CrossRef
  • Google Scholar

• 309

  Speiser PW Agdere L Ueshiba H White PC New MI . Aldosterone synthesis in salt-wasting congenital adrenal hyperplasia with complete absence of adrenal 21-hydroxylase. N Engl J Med. (1991) 324:145–9. doi: 10.1056/NEJM199101173240302

  • CrossRef
  • Google Scholar

• 310

  Falhammar H Nordenström A . Nonclassic congenital adrenal hyperplasia due to 21-hydroxylase deficiency: clinical presentation, diagnosis, treatment, and outcome. Endocrine. (2015) 50:32–50. doi: 10.1007/s12020-015-0656-0

  • CrossRef
  • Google Scholar

• 311

  Visseren FLJ Mach F Smulders YM Carballo D Koskinas KC Bäck M et al . 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. (2021) 42:3227–337. doi: 10.1093/eurheartj/ehab484

  • CrossRef
  • Google Scholar

• 312

  Mapas-Dimaya AC Agdere L Bahtiyar G Mejia JO Sacerdote AS . Metformin-responsive classic salt-losing congenital adrenal hyperplasia due to 21-hydroxylase deficiency: a case report. Endocr Pract. (2008) 14:889–91. doi: 10.4158/EP.14.7.889

  • CrossRef
  • Google Scholar

• 313

  Krysiak R Okopien B . The effect of metformin on androgen production in diabetic women with non-classic congenital adrenal hyperplasia. Exp Clin Endocrinol Diabetes. (2014) 122:568–71. doi: 10.1055/s-0034-1382048

  • CrossRef
  • Google Scholar

• 314

  Seagroves A Ross HM Vidmar AP Geffner ME Kim WS Hwang D et al . Weight Loss During Topiramate Treatment in a Severely Obese Adolescent with Congenital Adrenal Hyperplasia and Migraine. J Clin Res Pediatr Endocrinol. (2023) 15:81–5. doi: 10.4274/jcrpe.galenos.2021.2020.0310

  • CrossRef
  • Google Scholar

• 315

  Mallappa A Nella AA Kumar P Brooks KM Perritt AF Ling A et al . Alterations in Hydrocortisone Pharmacokinetics in a Patient With Congenital Adrenal Hyperplasia Following Bariatric Surgery. J Endocr Soc. (2017) 1:994–1001. doi: 10.1210/js.2017-00215

  • CrossRef
  • Google Scholar

• 316

  Kalani A Thomas N Sacerdote A Bahtiyar G . Roux-en-Y gastric bypass in the treatment of non-classic congenital adrenal hyperplasia due to 11-hydroxylase deficiency. BMJ Case Rep. (2013) 2013. doi: 10.1136/bcr-2012-008416

  • CrossRef
  • Google Scholar

• 317

  Krysiak R Kowalcze K Bednarska-Czerwińska A Okopień B . The Effect of Simvastatin on Plasma Steroid Hormone Levels in Metformin-Treated Women with Non-Classic Congenital Adrenal Hyperplasia. Exp Clin Endocrinol Diabetes. (2016) 124:215–9. doi: 10.1055/s-0035-1569375

  • CrossRef
  • Google Scholar

• 318

  Krysiak R Kowalcze K Bednarska-Czerwińska A Okopień B . The effect of atorvastatin on cardiometabolic risk factors in women with non-classic congenital adrenal hyperplasia: A pilot study. Pharmacol Rep. (2019) 71:417–21. doi: 10.1016/j.pharep.2019.01.014

  • CrossRef
  • Google Scholar

• 319

  Selva-O’Callaghan A Alvarado-Cardenas M Pinal-Fernández I Trallero-Araguás E Milisenda JC Martínez M et al . Statin-induced myalgia and myositis: an update on pathogenesis and clinical recommendations. Expert Rev Clin Immunol. (2018) 14:215–24. doi: 10.1080/1744666X.2018.1440206

  • CrossRef
  • Google Scholar

• 320

  Gupta A Gupta Y . Glucocorticoid-induced myopathy: Pathophysiology, diagnosis, and treatment. Indian J Endocrinol Metab. (2013) 17:913–6. doi: 10.4103/2230-8210.117215

  • CrossRef
  • Google Scholar

• 321

  Lévy BI Mourad JJ . Renin Angiotensin Blockers and Cardiac Protection: From Basis to Clinical Trials. Am J Hypertens. (2022) 35:293–302. doi: 10.1093/ajh/hpab108

  • CrossRef
  • Google Scholar

• 322

  Nehme A Zouein FA Zayeri ZD Zibara K . An Update on the Tissue Renin Angiotensin System and Its Role in Physiology and Pathology. J Cardiovasc Dev Dis. (2019) 6. doi: 10.3390/jcdd6020014

  • CrossRef
  • Google Scholar

• 323

  Katsimardou A Imprialos K Stavropoulos K Sachinidis A Doumas M Athyros V . Hypertension in Metabolic Syndrome: Novel Insights. Curr Hypertens Rev. (2020) 16:12–8. doi: 10.2174/1573402115666190415161813

  • CrossRef
  • Google Scholar

• 324

  Godfraind T . Discovery and Development of Calcium Channel Blockers. Front Pharmacol. (2017) 8:286. doi: 10.3389/fphar.2017.00286

  • CrossRef
  • Google Scholar